WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

6th Annual

05-06 March 2013 05-06 March Conference Guide

www.sachsforum.com CEO FORUM CEO FORUM Hilton Zurich Airport Hotel

PARTNERING & INVESTING for PARTNERING EUROPEAN LIFE SCIENCE EUROPEAN M U R O F O E C E C N E I C S E F I L N A E P O R U E WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u . Please bring with The one-to-one meetings are being held in the La Place A and B. the laptop Should you have any queries about your schedule, you a copy of your diary. situated by the meeting tables is available for your assistance. The registration desk is open from 8am on both days although you are welcome to join the a copy Please collect of the agenda for information on timing and room event at any time. allocation for each session. Wireless Internet connection is available throughout the venue for the duration of the event. Please ask for an access code at the registration desk. General Information • • •  Sachs Associates are delighted to welcome you to the 6th Annual European Life Science CEO Annual Associates to welcome you to the 6th are delighted Sachs the forum once Following its success from previous years, Forum for Partnering & Investing. again provides access to an exciting cross-section of venture-funded and small-cap companies with leading investors and pharmas. Europe Investor Annual Biotech in our This exclusive and transactional event compliments focus but with added industry, on Partnering & the pharmaceutical held later in the year, Forum, feature presentations representatives from Big Pharma demonstrating their current and future partnering strategies case studies. through thought-provoking programme features a series of panels and presentations from leading investment, This year’s the evolving highlighting the current issues surrounding pharmaceutical and biotech companies, Oncology and Biomedical Investment, Vaccines, Partnering activity, Finance and M&A market, Biotech providing an expert outlook on Europe’s and includes special keynote speeches, Presentations and more Workshop the event holds exclusive Partnering In addition, industry. than 60 exclusive company presentations from an exciting and diverse range of publicly listed partners. looking to raise finance and/or find and private life science companies, Sachs Associates are delighted to welcome you to the: are delighted to welcome you to Sachs Associates Annual 6th Science CEO Life European & Investing Partnering Forum for 5th - 6th March 2013 Hotel Airport Hilton Zurich Request for Presentations Please use the agenda to mark off presentations that you are interested in and email your request will endeavour to send you the requested We to [email protected] after the conference. presentations as soon as we have been granted permission to do so by that specific presenter. Please note that we DO NOT have copies of the slides thatconference. are shown during the Welcome WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS t back :: next u

• Big Pharma Approach to Innovation • Cancer Stem Cells Diagnostics & Image Technologies – Device, • Cancer Tech • Deal Making and Investment • Immunotherapies & Cancer Vaccines • Israel Bio-Med Oncology and Diagnostics • Personalised Partnerships • Public-Private & Directions Research – Advances • Translational For regular updates, sponsorship, presenting and attending opportunities presenting and attending opportunities sponsorship, For regular updates, regarding anyand further information future events please contact of our Zoe Harris on [email protected] Events Diary Events 30th September - 1st October 2013 • Zurich Featuring our core Investor Forum will once again the Biotech in Europe be held in Zurich. Back for its 13th year, with presenting opportunities for over 60 public analysts & media, an audience of over 400 investors, sponsors, this event is a Partnering and more, and private companies and panel themes including Finance & Investment, must for all key players in the Biotech and Pharma industry. The forum will be an excellent platform for companies to raise their profile by promoting their interests to the Facilitated one-on-one meeting system and networking receptions, by its successful larger financial community. and the event will help build strong and meaningful business relationships through face to face communication, advisors analysts, leading global investors, promises to be a great opportunity to meet emerging companies, Panel discussions with participation from industry leaders and experts in their and Big Pharma representatives. makes the Biotech In Europe Investor Forum an excellent way to gain insight and keep up to date with sector, partnering and investment and current industry trends. www.sachsforum.com/zurich12/index.html event at: View last year’s 13th Annual Forum Investor Biotech in Europe Collaboration & Investment in Drug Development & Investment in Collaboration Copley Place • Boston Westin The 21st - 22nd May 2013 • from cancer research to bring together thought leaders The Sachs Cancer Bio Partnering Forum is designed We and biotech to facilitate pharma partnering and funding/investment. patient advocacy groups, institutes, expect around 300 delegates meeting system and meeting facilities to make the event and there is an online patient advocacy groups, There will also be a track of presentations by research institutes, transactional. licensing/investment.The Forum will feature seeking an pharmaceutical companies on partnering and biotech’s online one-to-one meeting system with designated meeting space available to all attendees. Forum will cover the following topics in the program: Sachs Cancer Bio Partnering Annual FORUM PARTNERING CANCER BIO Sector, Promoting Public & Private WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Maxwell Biotech Venture Fund Venture Maxwell Biotech Managing Director, Eliseev, Alexey Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the His career includes over 17 years of experience biotechnology in industryacademia, Massachusetts Technology. Institute of and venture capital. Eliseev has been working in the Dr. United States and Europe Following since three 1992. years of postdoctoral research in Germany as an Alexander von Humboldt Fellow and in the US, he joined faculty at the department of Medicinal Chemistry, (later Therascope company the co-founded he 1999 In 2000. in tenure awarded was he where 1995 in Buffaloat University Alantos Pharmaceuticals) with a number of prominent founders including French Nobel company used a Laureatenovel drug discovery Jean-Marie technology developed in Lehn. several academic The labs, including group Alantos Eliseev’s in Buffalo. division. US its of President and Alantos of Officer Technology Chief became later and 2000 in company the joined He Amgen in 2007 for $300 million. was acquired by AC including entrepreneur, and scientist a as companies biotech several starting in involved was Alexey years recent the Over Immune (Switzerland) and Boston BioCom Alexey (US). has been working with the Russian-based numerous Maxwell managed Biotech Venture has and Fund the of activity international for responsible is He 2009. since Director Managing its as Fund deals with portfolio companies in the US and Europe. Menarini Pharma President, Slade, Andrew manufacturing and R&D biotechnology the for responsible is he role, this In Biotech. Menarini of President is Slade Andrew Dr. undertaken by Menarini and in the in-licensing of biotech products. Slade Dr. was previously Head of Manufacturing for a major Biologics company and before that was employed by GSK in various senior product development and operational roles. He studied biochemistry and enzymology. General Partner, TVM Capital General Partner, Goll, Alexandra Alexandra joined TVM Capital in early 1998 has been responsible for more than 20 TVM Capital life science investments. successful investments Switzerland) and led Actelion the Ltd firm’s (Allschwil, lead investment in TVM Capital’s She initiated acted Capital TVM – Sciences Gilead to sold was which Inc. Pharmasset and Novartis, to sold Inc. Pharmaceuticals, Idenix in as a lead investor in She both also cases. initiated and managed the investment in EUSA recently Pharma sold Ltd., to Jazz Pharmaceuticals Inc. Currently, Dr. Goll serves on the Board of Directors of Albireo (Gothenburg, Cerenis Sweden), Therapeutics Biovertis France (Toulouse, AG and Ann MI). Arbor, (Vienna, She Austria) also and represents the interests of TVM Capital with Addex Pharmaceuticals SA (Geneva, Switzerland), MediGene AG (Martinsried), Newron Pharmaceuticals SpA, (Bresso, Italy) and Germany). AG (Munich, Wilex Prior to her affiliation with TVM Capital, Goll Dr. was the Global Business Leaderfor for HIVstrategic andmarketing and CMV, and was Amgen), business responsible with development agreement an for (under Virology Neupogen® as at such products Roche of strategies Ltd. commercialization managing in and development Basel. She had been involved in clinical Hivid®, Cymevene® Goll and holds Dr. Valcyte®. a degree in pharmacy from the Free University of Berlin, and position wrote post-doctoral her a with honored also was She Marburg. of University Philipps at sciences natural in dissertation doctoral Foundation for fundamental research in medicine. supported by the Boehringer-Ingelheim WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Vice President, Corporate Development, Quintiles Corporate Development, Vice President, Ben Cons, Ben Cons PhD, Global Vice President Quintiles Corporate Development structures and delivers managed partnerships with pharmaceutical and biotechnology industries. parties. all for value realize that companies between solutions partnership developing in adept is he leader, team innovative An drive to commercialization and development drug pharmaceutical in expertise his bringing 1996, in Quintiles joined Cons Dr. Cons expanded his research experience in molecular pharmacology Dr. Early corporate on development in goals. his career, through a position in drug at he development Wellcome, Glaxo developed for Later, an AG. Schering expertise in marketing and business development. Polytechnic, Portsmouth from honors with sciences biological in degree bachelor’s a acquired Cons Dr. U.K., the in Educated and then continued his studies to earn a doctorate in molecular pharmacology department of Southampton University. within the physiology and pharmacology CEO, Virometix CEO, Arin Ghasparian, Virometix’ becoming Before technology. Particle Virus-Like Synthetic Virometix developed and co-invented Ghasparian Arin Dr CEO in 2012, he served as Chief Scientific Officer and was responsible for all R&D activites of established company, R&D partnerships and brought Virometix programs from research to proof-of-concept in he animals. Prior worked as to a founding researcher Virometix at the University of Zurich, where he a developed background new in approaches organic to chemistry vaccine and design. received He a has Doctorate in biochemistry participated base in this area. in several entrepreneurship and business courses to expand his knowledge from the University of Zurich. He has also Sofinnova Partners Sofinnova Managing Partner, Antoine Papiernik, investor initial an been has Antoine 1997. in joined he which Partners, Sofinnova atManaging Partner a is Papiernik Antoine and active board member in public companies like Addex, Actelion, Orexo, NovusPharma (then sold to CTI), Movetis (then sold to Shire) and Stentys, which went public respectively on the Zürich stock exchange, the Stockholm stock the Milan the Nuovo Belgium Mercato, Stock Exchange in and exchange, Cotherix EuroNext (initiallyParis, then NASDAQsold to listed, of member board a is and in invested also has He Aventis). Sanofi to (sold Fovea and Medtronic) to (sold CoreValve Actelion), private Antoine companies has MD Mainstay an EOS, CoAxia, Start, and MBA Recor. from Wharton the School of Business, University of Pennsylvania. Managing Director, Investement Banking, USB Investement Banking, Managing Director, Anthony Hartley, mainly and London in based is He Group. Healthcare Global Bank’s Investment UBS in Director Managing a is Hartley Anthony focuses on pharmaceutical and biotechnology companies in Europe. Anthony joined UBS in 2012 from Morgan Stanley and has spent predominantly12 years in healthcare investment banking, advising healthcare clients with a primary focus on the pharmaceutical and biopharma sectors. Anthony received pharmaceutical a the in years 7 of Doctorate total a spent Anthony (D.Phil) banking, investment in in career his to Prior Pharmacology School. Business Manchester from The University of Oxford, and an AstraZeneca GSK and industry MBA working in a variety of research and commercial roles at Pfizer, (Distinction) from Novartis Venture Fund Venture Managing Partner in Basel, Novartis Anja Konig, Prior Pacific. Asia to presence fund’s the expanding for responsible also and Europe and Switzerland in active is Konig Anja Dr to joining Novartis she was an Associate Partner at McKinsey and a Company, global where consultancy, she worked with companies in health care in the Europe US, and Anja EmergingKönig is Markets. a scientist by training and holds a PhD works in and Nabriva, and Heptares, Diagnoplex, Covagen, Bicycle, of boards the on serves Anja University. Cornell from physics Therapeutics and S*BIO. Qurient Polyphor, PharmAbcine, Neomics, MerLion, with Destiny, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ability Pharmaceuticals Speakers Vice Presdient, Global Head of Strategic Alliances, Global Head of Strategic Vice Presdient, Wilson, Charles Inc. Institute for BioMedical Research, Novartis Charles Wilson serves as the Global Head access to collaborations of biotech processes, Strategic disease understand Alliances, to relationships leading academic include efforts a Partnering Novartis. group responsible for research partnering at Chuck Novartis, joining to Prior proof-of-concept. clinical to prior compounds of in-licensing and technologies, discovery drug Officer Technology initiallyResponsible Chief its as companya focused aptameron therapeutics. Archemix, foundedled and for developing the technologycompany’s platform and managing its drug discovery efforts, he moved into a business role focused on partnering with pharma and biotech companies. Before moving into Department industry, of Chuck and Cellular, Molecular, Developmental was Biology a at professor the University in of the California, Santa Cruz where his group determined the first x-ray structures Formally of trainedaptamers in bound structural to biology their targets. and molecular Chuck received his PhD from UCSF and his post-doctoral training at MGH. biology, Founder & CEO, Carles Domènech, and Barcelona of University Autonomous the from honors) class (first biology in degree BSs/MSc a obtained Domènech Carles also a PhD degree in cellular biology from the working same at University, the Council of Science Research (CSIC). He has atadditional business training programs. ESADE business school and other business Carles started developing his career in cancer research at CSIC in Barcelona (1985-89) and at Memorial Sloan-Kettering (1990-1992). York Cancer Center in New Carles has 15 years international experience in business development and licensing held senior in positions at the the pharmaceutical Barcelona pharmaceutical industry. companies He Almirall, SA (1992-2003, Manager and Head, Business and Licensing). Business Development Director, SA (2005-2007, Development and Licensing) and Lacer, Carles has also 4 years’ experience in collaborating with biotech government innovation agencies. Between venture 2004 and 2005 capital he was Biotech Director, Investments at and the business angels seed venture associations capital firm Barcelona During SCRSA. Emprèn, 2008-2009 and he collaborated with agencies of has the Government also been Valorization Investment and and and as Enterprise Transfer Managing Growth. Director, Technology of Catalonia as Director, He had under his responsibility the seed venture capital company Invertec, SA and the entrepreneurship finance programs Since July in biotech investments. 2009 he also advises Keiretsu Forum Barcelona Genesis Capital and Concept Capital. SL to become its Chief Executive Officer in September 2009. Ability Pharmaceuticals, In 2009 Carles cofounded Skolkovo Foundation Skolkovo Biomedical Cluster, Chris Janssen, Director of Science and Innovation, Starting with a career in BioMedical research, spending Chris some years Janssen in academia, Chris has moved on to extensive business, founding a experience biotech Following company. on in from success science in development. research After and business, he has led national development efforts in national development BioMedical program technologies, for quantitativelastly biology as and medicine director at for Scotland’s national the academy, the Royal Society of with Edinburgh, particular emphasis on commercialisation and business Chris integration. has participated in governmental creating include achievements His Service. Health National the at groups oversight in and groups, advisoryparliamentary and access for business to integrated health care and science information, focusing public-private partnership support funding for development of cutting edge science research in SMEs, and setting Since and academia, mid-2011 industry. Chris up has held the position collaborative of Director for Science networks & Innovation at between the BioMedical health care, Cluster’s the overseeing support, for areas thematic priority setting include remits His Russia. Skolkovo, Cluster Technologies part in the due diligence process for grants, working with major multi-nationals, and facilitating the creation of appropriate infrastructure for the Cluster’s participants. Chris sees his primary goals as identifying excellent science in the biomedical area in Russia, and facilitating its commercialisation, bringing cutting edge start-up companies to Russia, and assisting in creating the right infrastructure to necessary for growth successful of biomed business in Russia. Vantage Life Sciences Life Vantage Chris Britten, Managing Director, an biochemistry and in PhD a background, scientific a has He Science. Life Vantage of Director Managing the is Britten Chris acquisitions, of variety a negotiated having market Sciences Life the in contacts and experience huge gained has Chris MBA. divestments and strategic with partners around the world. alliances licences, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Immune Pharmaceuticals Speakers Daniel Teper CEO, Teper Daniel Dr is Daniel Teper the founder and currently the Chief Executive Officer of Immune and has been such since 2010. From was Managing a Partner York-based New Teper and Head of America North at 2005 Bionest to Dr. Partners,a 2010, Global Management Consulting firm, where he advised pharmaceutical Corporate Business Strategy, Development, Mergers & Acquisitions, New Product Development and and Commercialization. he public biotechnology companies withhad previously respect to been a New York based Partner at ISO Healththcare Consulting, later acquired by Monitor Group. Dr.Teper started his career in 1984 at at Novartis in Base, CH and then in the United States where responsibilities he help in growing management sales, marketing and eventually as returned to Vice Europe President as and Senior Head of Marketing & Head Sales at Glaxo France Dr.Teper and then as President of New Product Development for Cardiovascular Products. and Chief Operating Officer of Laboratoires Delagrange which was acquired by Synthelabo (now Sanofi). He tehn founded and was the CEO of WINTEC Pharma, a specialty which Pharmaceutical he company, sold part to Norgine (UK) and part to then as where RSCG Global, joined President, Worldwide, expanded Healthcare Teper HAVAS-EURO Galephar Dr. (Belgium). Euro Rscg operations internationally and advised pharmaceutical companies on Global Launches was of which and ophthalmology in specializing major company pharmaceutical a new NOVA), drugs. Dr. Euronext: (NYSE Novagali co-founded Teper from MBA an and University XI Paris from degree Pharmacy of Doctor a holds Teper Dr. Santen. Japan’s by acquired recently INSEAD where he was a J.Salomon scholar. Partner, Forbian Capital Partners Partner, Takke, Christina Christina holds Takke a PhD in Molecular Biology from the University of Cologne. She specialized in Functional Genomics and focused on early embryonic development. Christina completed a PhD thesis on cell-cell interactions during zebra fish neurogenesis and somitogenesis. After her internationally oriented academic responsible been she has career, and 2000 worked in team atScience Life a the NRW, Bio-Gen-Tec, joined She Consultant. Business a as Agency Governmental German for conducting scientific and clinical due diligence investigations and providing scientific support to our portfolio companies. Forbion’s as acts Christina NV. Amakem and BV arGEN-X AG, Pieris with positions board non-executive holds she Furthermore Compliance Officer. Index Venture Index Life Sciences, Associate, Daniel Bach, having joined the firm in 2007. Associate in the life sciences team, Daniel Bach is an areas of Dani’s interest range from metabolic diseases to virology and prior to joining Dani Index, was conducting research at the Ecole Polytechnique Federal de Lausanne (EPFL), where he worked system. immunodeficiency virus (HIV) and the human immune on the complex interactions between human Administration and a PhD in Molecular Biology the Universitat from de Barcelona. Dani holds a Master in Start-up Business Nodality Inc. Nodality Inc. VP BD, Daniel Dornbusch, Daniel Dornbusch has served in multiple management roles at and pharmaceutical, biotechnology, diagnostics companies including Novartis, Genentech, and Genzyme. Daniel has spent over 15 years in industry the biopharmaceutical in and diagnostics various roles including business management. Daniel joined Nodality from development, Novartis Diagnostics where he sales, held the position of marketing, Commercial Director of Latin transactions. corporate development business numerous completed he where development business development, in Novartis joined Daniel America. and commercial Before Novartis, Daniel held roles in business development at Cerimon Pharmaceuticals and Daniel led began a his marketing career Inc. team at at the Genentech, and Amerisource sales Bergen forcompany, an Inc., led business development corporate and management, product development, business in including roles numerous in served and Corporation Genzyme development. Daniel received his B.A. in Biology and English from Cornell M.A. University, from Tufts University School of from the Harvard Business School. and M.B.A. Medicine and Emerson College, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Bone Therapeutics Bone CEO, Enrico Bastianelli, Dr Bastianelli has a long standing experience in pharmaceutical industry in fieldsLicensing, Corporate asDevelopment broadand His Strategy. ascareer Salesstarted in &the Marketing,Pathology R&D, Department of the Erasme University Then he Hospital joined in Procter & Belgium. Gamble Pharmaceuticals where in he 1996, was involved in the marketing of where Co, & McKinsey for Consultant a became he 1999, In diseases. bone of field the in drugs over-the-counter and ethical he was involved in strategic and organizational missions for major pharmaceutical as the well as ProSkelia, for biotechnologyDevelopment Corporate VP companies all as worked Bastianelli Dr mid-2006, until 2002 in creation its From Europe. over with merger the after ProStrakan, became then (which disorders hormone and diseases bone on focused Aventis of spin-out a Scottish pharmaceutical company). Strakan, Since June 2006, he is Chief Executive Officerspecialized in the treatment of osteo-articular diseases using cell therapy. of Bone Therapeutics; a leading international biotechnlology company CEO, Bio-Holdings Ltd. CEO, Einat Zisman, and company transfer technology the Ltd., Development Services& Research Medical Hadasit of CEO the is Zisman Einat Dr commercial arm of Hadassah Medical Organization in Jerusalem, Israel. Prior to joining Zisman Hadasit, servedDr. as the theYeda, technology ZismanChief transfer alsoBusiness arm servedOfficerWeizmann of of Institute the at of Dr. Science. a range of senior positions in the Israeli among bio-tech them industry, managing managingprojects, research Business and Marshall overall the from MBA an holds Zisman Dr. academia. the in originated that projects of promotion and development Institute of a Science Weizmann PhD and in a ImmunologyB.Pharm from USA, the University of Southern California, School, initiating partnering, licensing, via value building in is expertise Zisman’s Dr. Jerusalem. of University Hebrew the from degree financing and marketing of early stage intellectual property. start-ups, MedGenesis Therapeutix Inc. Inc. Therapeutix MedGenesis Chairman & Chief Executive Officer, Mohr, Erich Erich Mohr, Ph.D., R.Psych. founded MedGenesis Therapeutix Inc. in 2006. He is medical experimental on service an therapeutics of historyfor internationally lengthy central a recognized has nervous and expert system panels advisory disorders regulatory in several and on has served and/or served chaired as has He the trials. principal clinical investigator on numerous largest pharmaceutical firms as well as a number of biotechnology companies. advisory boards for several of the world’s In 1995, Mohr Dr. founded CroMedica, a Canadian based global, full service CRO with a strong focus on System Central Disorders Nervous which became a global corporation with over 550 employees and officescompany merged with inPRA International 5 where he continents.served as InChief Scientific 2002, Officer the for a period of almost 4 years. In 2004 in the world. PRA International achieved listing on Nasdaq (PRAI) and is now one of the top 5 CRO’s of period a for NIH the at staff on also was Marylandand Bethesda, in Health of Institutes National the at trained was Mohr Dr. He four held years. an academic appointment as Professor of Medicine and Psychology at the University of Ottawa School of book chapters and abstracts books, Medicine until 2002 and is credited with over 150 publications, Mohr earned Dr. his doctorate in neuropsychology in 1982 and master of science degree in neuropsychology in 1980, both from the University of Victoria, British Columbia, Canada and obtained his undergraduate education at The University of the He is USA. the recipient California, of a Stockton, number ofPacific, academic and industry among them awards, the Legacy Victoria. from the University of Year) (Alumni of the Award President and CEO, Resverlogix Corp. President and CEO, Donald McCaffrey, discovery drug in experience of years 30 over has He Corp. Resverlogix of CEO & President, Co-Founder, is McCaffrey Donald biotechnology. including industries, multiple across management tradeshow and conference international and development, & Don has led Resverlogix through significant change and achievement from its initial days as a private company to becoming a TSX listed including company, raising over $185 million. In addition to garnering appropriate financing for Resverlogix’s aggressive Don development has plan, strategically directed the Company in its discussions with top global pharmaceutical operationscorporate in expertise Don’s platforms. technologykey its for markets therapeutic new creating while companies, has attracted an international team of R&D Under experts to Resverlogix. disease. This cardiovascular scientific of treatment and the operational for drugs expertise of has class pioneered new a in first be to potential the has which drug a RVX-208, Pioneer award. Technology WEF his guidance Resverlogix has won multiple awards including the 2008 nominatedforErnst was he as peers, and community business bythe recognized havebeen accomplishments career Don’s He is a twice. contributor to community Year Entrepreneur non-profitWay, of organizationsthe including theYoung United & and Calgary Urban Project Society Literacy Program. Education Matters, Hospital, Alberta Children’s Mount Royal College, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers CEO and Founder, PharmaVentures CEO and Founder, Walton, Fintan Dr Walton is Fintan the Founder and CEO He of was PharmaVentures. educated at the University of Michigan (US) Trinity and positions management in biotechnology in experience commercial broad gained he subsequently and Ireland), (Dublin, College at Bass and Celltech plc (1982-1992). As an Dr entrepreneur, Walton co-founded CONNECT Pharma in strategic including making 1992, deal of a aspects all in company worldwide companies biotechnology and pharmaceutical assisting on focused alliances, Mergers & Acquisitions and equity financing. In 1997 the company became PharmaVentures.Clients Hiscountries. 37 in forcompanies assignments 600 than more delivering companybasis, global a on clients chip blue with worked has have included major pharmaceutical and biotechnology companies as well device, as generic and diversifiedOTC companies. chemicalHis clients corporations,have medical also included major banks, investment/merchant banks, and private equity and venture Although main capital Fintan’s focus groups. is his role as Chief Executive Officer of he PharmaVentures, actively participates in many consultancy assignments. Florian Schödel is the development founder of the Philimmune in LLC, a consulting teams firmwhich leading providesin strategic adviceexperience insuccessful the developmentof of years 20 > has Florian pharmaceuticals. and vaccines biologics, of vaccines and biologics and biotech industry in the pharmaceutical and in academia. His passion is preventative medicine and the use of modern science and technology for the improvement of public health – especially in the development of preventative and therapeutic vaccines and biologics. Florian has a track record in running forming international scientificstrategic partnerships and alliances, in andtarget identification and in all operational steps of clinical and pre-clinical organizations, in businessdevelopment. and strategic planning, for national and international with interacts routinely and licensure for studies clinical of execution and design the directed has He regulatory agencies. Florian has led the clinical teams responsible for several successful vaccine filings. A physician and microbiologist by training, Florian was a VP in Vaccines Clinical Research of Merck Research Laboratories before he founded Philimmune. and Immunology Transplantation in doctorates earned and Munich, University, Technical the at medicine in graduated Florian at appointments faculty adjunct holds He (LMU). Munich of University the from habil.) med. Dr. med. (Dr. Microbiology Medical atresearch atScripps, the the Max-Planck LMU Institute and Florian’s forat Biochemistry, the ASU. Biodesign Center of the WRAIR and INSERM focused on hepatitis B and on malaria novel and recombinant vaccines against diseases such as hepB, typhoid. Florian joined Merck Research Laboratories in 1996 as Director Vaccine Clinical Research leading EU vaccine clinical trials vaccines. shingles and combination rubella mumps, measles, varicella, and vaccines rotavirus of development clinical the and As the clinical liaison to an EU joint venture (SP-MSD) he participated in the development of pediatric combination vaccines. Florian Schödel, CEO, Phillimmune LLC Florian Schödel, Oxford BioTherapeutics AG BioTherapeutics Oxford Chief Operations Officer, Villar, Esteban Pombo 20 over for Novartis at was Pombo-Villar Dr OBT, joining to Prior Biotherapeutics. Oxford for Officer Operations Chief is Esteban of Head was he recently Most managingalliances. and creating of aspects all on focused he which of years 12 last the years, proof-of-concept to up alliances for responsible (NIBR), Research Biomedical for Institute Novartis the at Management Alliance in man. He has a PhD in organic chemistry and completed postdoctoral studies at the ETH in Zurich before joining Sandoz Neuroscience Research in Basel in At 1988. Sandoz he worked on drug discovery projects as well as leading collaborative Pombo-Villar is a Fellow of the Royal Society of Chemistry. Dr projects investigating potential of emerging the technologies. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Irena Melnikova joined Prior Burrill to & Russia. joining Company Burrill in & October Company, 2012 as Managing Director, she served as Director of Strategy and External Innovation at Sanofi. Irena Previously, was a Principal in the Life Science team of TVM Capital, a global venture capital firm. Atinvolved TVM,in deal sheorigination and new investment was opportunity evaluation and actively participated in the management TVM of Capital investments in the United States. Prior to TVM Capital, she was a member of the team at biopharma Leerink She Swann. also produced investment and launched a banking new series of syndicated reports for the Entitledfirm. Future in R&D and corporate shaping issues technology and business of analysis and insight with clients provided reports these Focus, pipelines and alliances. strategies, Prior to Irena Leerink was Swann, a Research Manager at Life a Science subsidiaryInsights, the of leading IDC, technology market research As company. a project leader at Pharmaceuticals TransForm (acquired by Johnson & Johnson), she was Amyloidoses. and funded by DARPA, Constructs, Tissue including Engineered responsible for running several programs, section Couch” “Analyst the to contributor regular a is and journals peer-reviewed in manuscripts 20 over published has Irena of University Mendeleev the from engineering chemical in M.S. an holds She Discoverymagazine. Drug in Reviews Nature of Texas. in molecular medicine/molecular biology from the University of of Russia and a Ph.D. Technology Chemical Irena Melnikova, Managing Burrill & Company Director Russia, Melnikova, Irena Neurophage Pharmaceuticals VP and Chief Business Officer, Executive Hampus Hillerstrom, Hampus Hillerstrom is a co-founder and board member of NeuroPhage and serves as Executive Vice President and Chief heBusiness Previously, spentOfficer. 3 years as an associate at leading European biotech venture capital firm HealthCap where he participated in Hillerstrom a large Mr. Previously number trials. of clinical III investment Phase transactions to leading including decision-making evaluate several to IPOs. AstraZeneca More at recently project Hillerstrom a Mr. spearheaded was a partner in the Zurich-based consulting boutique Venture Valuation specialized in the assessment biotech and companies. For valuation a of year prior to that he worked University the in from Finance and Economics mergers in Masters a holds and Hillerstrom acquisitions Mr. at teams. industry chemicals the and pharmaceutical investment bank Lazard in the of St. Gallen, an MBA from Harvard Business School, and an MSc in Health Sciences Medical School (HST). and Technology from MIT/Harvard Director Business Development Oncology, Global Licensing & Business Development, & Business Development, Global Licensing Oncology, Director Business Development Vignon, Guillaume Serono Merck Mr Guillaume Vignon Guillaume is position, this to Director Prior of Oncology. of field Business the in Development transactions strategic complex Oncologyof terms the with negotiating and structures Merck Serono, responsible for designing deal was responsible Director for of partnerships StrategicTransactions, of pre-clinical stage enabling assets, and technologies, Merck for partnerships key several successfully closed Guillaume Serono, Merck at career his During diagnostics. companion discovery. Antibody and Companion diagnostic, Serono in the field of Oncology, Before his positions as global transactor, Guillaume served as inhouse consultant and for commercial operations BU Oncology, implementation, leading several assignments in the field ofMerck management strategy, KGaA, Damstadt, Germany, business planning BU Oncology. Molecular and Biochemistry in Ph.D. a and USA, Cambridge, School, Business International Hult from MBA an holds Guillaume France. Paris, BiologyInstitute, from the University of Paris 6/ Pasteur HemaCore LLC CEO, HemaCore Igor Pivovarov, Board of several companies. and Co-Founder & Member of Igor Pivovarov is CEO & Co-Founder of HemaCore Igor has 6 years basic research experience in biophysics, mathematical CEO and he has raised over $22M in investments. CMO, CTO, modeling. engineer, 15 years business experience as an HemaCore is a biotech company which develops medical devices and assays The for Company hematology. was invested in by RUSNANO to bring it to the Thrombodynamics market. is a new global assay for monitoring and prognosis coagulation disorders and finding out risks of bleeding and thrombosis. of blood WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u

Telormedix S.A. Telormedix ViroGates Speakers Johanna Holldack, CEO, Johanna Holldack, Johanna Holidack has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in Her experience includes management and both executive positions start-up and atlarge pharma Behringwerke, companies. MediGene and Borean Pharma. Chiron, pediatrician. Certified Board a is and Germany Gottingen, in Georg-August-University from degree medical a has Holldack Dr. In addition, she has held positions as an assistant professor at the University of Essen, research Krebshilfe and a research associate at Harvard Medical School. fellow for the Deutsche pharmaceutical/biotech clients in commercial technical, due diligence and financial For transactions. 10years Jason was a venture the with latterly transactions science life private 30 over completing in involvement direct with investor capital venture capital fund of Nestle. Jason has been a board member of a number of biotech companies and has firsthand experience of business development and licensing. Jason leads the life science focus of Deloitte Corporate Finance in Switzerland. management and venture capital. consulting sector spanning R&D, He has 20 years of experience in the pharmaceutical Jason began his career in drug discovery with Eli Lilly and then moved to PA Consulting Group where he advised Jakob Knudsen, CEO, Knudsen, Jakob Danish a Ltd. Egalet of CFO & CCO previously was Jakob 2011. April in ViroGates of CEO as role his assumed Knudsen Jakob based biotech company focusing on development of pain products. Jakob oversaw all commercial operations including IP and Financing, and was responsible for entering into multiple commercial agreements). Prior collaborations to (licensing this Jakob and was heading feasibility the stage Corporate Business Development function at ALK-Abelló A/S, a Danish biopharmaceutical Jakob company. was responsible for ALK’s licensing and M&A deals. Before this Jakob held positions within sales and marketing with the company. Jakob is a lawyer by training and he also holds an MBA from Imperial Deloitte Advisory Initiative, Head of Life Sciences Jason Rushton, College, UK. College, xecutive Director, Head European External Scientific Affairs, Worldwide Licensing, Worldwide MSD Affairs, Head European External Scientific xecutive Director, Tonnaer, Jeroen Medical the from pharmacology in PhD a and Nijmegen of University the from biology in MSc an obtained PhD Tonnaer Jeroen Faculty (Rudolf Magnus Institute for Pharmacology) of the University of Part Utrecht. of his PhD work was performed at the INSERM laboratories in Paris. Jeroen joined Organon as a neuroscientist in As Assistant-Manager 1982. of the CNS Program he was responsible for the pre/early clinical development of SAPHRIS®/SYCREST® (asenapine). He held further Head positions Schering-Plough, by Organon of as acquisition upon Head and, Alliances DMPK, Executive Research Global Director Executive Toxicology, Director Discovery Collaborations Europe. In the latter role he led the team that facilitated licensing and collaborative efforts for for liaison the business the was and field Health Women’s the on personally focused Europe, in based scientists Schering-Plough TI Pharma. Schering-Plough in the consortium 2010 February in organization Licensing Worldwide Merck’s joined Jeroen Merck, by acquisition Schering-Plough’s Following identification the in driver the been has team this then Since team. Affairs Scientific External European the of head become to AiCuris and Delphi Genetics. Ablynx, and execution of several major licensing and partnering deals including those with WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers ImmunoVaccine, Inc. ImmunoVaccine, CEO, Trizzino, John John B.S., Trizzino M.B.A., is a senior executive with more than 25 years of experience advancing strategic initiatives for publicly traded biotechnology companies, primarily within the vaccine market. Prior to joining Immunovaccine, he was the Senior Vice President at Novavax Inc., where he provided strategic direction venture and and successfully licensing negotiated agreements, including profitablea joint $179M BARDA contract. Prior to joining Novavax, Trizzino held Mr. senior executive positions at MedImmune Inc., which was acquired by AstraZeneca, and ID BioMedical Inc., which is now part of GlaxoSmithKline Inc. He began his extensive career in vaccines at Henry Schein Inc. leading commercial marketing efforts Island Long of graduate a is Trizzino Mr. agreements. distribution and commercialization successful of series a executing and University and received his degree master’s in business administrationLeonard Stern University’s N. from School York New of Business. Torreya Partners Torreya John Cullity Principal, licensing, M&A, in services providing firm advisory sciences life a Partners, Torreya of office York New the at works Cullity John and corporate finance. Previously he was at Sanofi Aventis where he coordinated $3John diabetes. led Aventis’ Sanofi strategic pricing billion department managing the transactions $15billion and portfolio, placing in valuations on oncology and the pipeline. He was previously at Schering-Plough in strategic pricing and health economics. John has also worked for AT WHO World Bank, and as Kearney, an internist in UK and Australia. He holds MBA Wharton, MSc (Econs) from LSE, Medical Australia. Western and medical degree University of from of Physicians UK, Boards from Royal College CEO, uniQure CEO, Aldag, Jörn Jorn Aldag joined uniQure’s predecessor company AMT in October 2009. He including has the led build-up uniQure’s of corporate its development gene therapy pipeline, the marketing authorization process at dilutive EMA and for non-dilutive Glybera, and financingseveral transactions. Before joining uniQure he was from instrumentalEVT), 1997 to 2000 as CFO inand from 2001 to 2009 as buildingPresident and EVT CEO. designed and implemented Evoteca cutting AG (FSE: edge small molecule technology platform, became a leader in drug discovery Aldag served Jörn Prior in andto various asEvotec, financial Businesspipeline. management Director AG, positions at MAN services and developed a promising CNS at the Treuhandanstalt, agency responsible for privatizing the East German economy after the German reunification. Jörn and a member Switzerland, of the Board AldagZurich, of is Directors Chairman of AG, of the Molecular DESERTEC Partners He holds business Germany. Hamburg, Foundation, degrees from the Harvard Business School and the European Business School. Forest Laboratories Forest Executive Director Business Development, Jonathan Garen, Jonathan Garen is an Executive Director of Business Development at Forest Laboratories, where Inc., he has worked since opportunities business new for transactions of negotiation and evaluation, identification, the include responsibilities His 2003. neurology, of fields the in acquisitions and licensing including development, of stages and areas therapeutic of range wide a in department Licensing Global the in Director Jonathan a was Forest, to Prior oncology metabolic and diseases. inflammation, stage early for exchange licensing online an TechEx, of President Vice and founder a was Jonathan Corporation. Pharmacia at Master his earned Jonathan University. Yale of office licensing technology the at Associate Licensing a was and opportunities, of Environmental Sciences University from Yale and his Bachelor of Science in Physics from the Massachusetts Institute of Technology. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers OCT Clinical Trials OCT Clinical Head of Business Development, Julia Sardaryan, Julia Sardaryan graduated from St-Petersburg State Julia University holds in a 2007. masters degree in English Linguistics, Julia started Translation. her career in pharmaceutical business at OCT in Through 2007. the years she has demonstrated career development being Clinical Trials Coordinator, Business Development at OCT. Development Manager and then Director of Business As Director of Business Development, Julia is responsible for new business opportunities assessment and She client manages relations development and of management;budget new negotiations. relations advertising, with she supervises OCT’s clients from Sardaryanall over Ms. has the dedicated world. much of her career to attracting pharmaceutical companies all conducting of challenges and specifics the knows Julia region. CEE and CIS Russia, in trials clinical conduct to world the over clinical trials in this region. Estonia Lithuania, Latvia, Bulgaria, OCT Belarus, is an experienced full-service Ukraine, CRO successfully working in Russia, pulmonology, OCT provides since the 2005. full-scale range of services biotechnology to and disorders, pharmaceutical, medical device companies. autoimmune cardiology, neurology, (oncology, areas therapeutic of range wide a in experienced is OCT etc.); endocrinology, in gastroenterology, phase I-IV studies, bioequivalence trials, pre-clinical studies. OCT has a record of studies with drugs, which were approved by FDA and EMEA afterwards; some of the trials were conducted in the Russian Federation exclusively. Capricorn Ventures Capricorn Partner, Venture Katya Smirnyagina, Dr Ekaterina (Katya) Smirnyagina PhD University Stanford the at training scientific her completed Katya in Russia). University, State Moscow Biochemistry(Lomonosov Cellular & Molecular Biology (University of Wisconsin-Madison, School of Medicine, then worked USA), in management consulting and BS biotech business development. In 2002-12 in she was with CA. a healthcare focused venture capital fund in San Francisco, Alta Partners, Kieran Murphy joined GE in April 2008 as a result of the acquisition Sciences Life of the of Whatman CEO appointed being before roles plc commercial of number a where held he acquisition the he Following 2007. earlyhad served as CEO since business in early 2011. Adprotech, including businesses Biotechnology UK in positions CEO of number a held Kieran Whatman, in position his to Prior ML Laboratories and Innovata plc. He has been involved in the life sciences industry since Vaccines. joining Animal and Novartis Vericore Janssen Mallinckrodt, Pharmaceutical in 1989. He served as CEO at and Science of Institute Manchester of University The and Dublin College University graduateof a is he Ireland, Cork, in Born Technology. GE Healthcare Life Sciences GE Healthcare President & CEO, Murphy, Kieran Covagen AG Covagen CEO and Co-Founder, Julian Bertschinger, Julian is co-founder and CEO of Covagen. After his studies in molecular biology Bertschinger joined the group and Dario of Neri Prof. at the Institute of biochemistry Pharmaceutical Sciences ETH Zurich as student. a Ph.D. at ETH Zurich, Julian There he co-invented Covalent DNA Display After technology. obtaining his Ph.D. in May 2005, he continued Covalent DNA developing Display as a postdoctoral fellow in Prof. Dario group. Neri’s In June 2006, Julian Bertschinger was selected from more than 100 applicants as one of the Leaders winners Venture Prize of founded the This by the Gebert Rüf Stiftung. enabled him to join a training program Boston area (USA) with a course in entrepreneurship at in the Babson College. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Amakem NV Amakem Speakers Kieran Rooney, CBO, Rooney, Kieran Dr Kieran Amakem Rooney NV joined as Chief Business Officer Over in the 2012. past 6 years he has provided commercial and transactional consulting support to over consultancy firm, 30 Halo BioConsulting pharma/biotech Ltd. Prior companies and to founding life across a portfoliosupporting commercial activities companies. of UK-based life science inHalo sciences 2007, investors he was a through Consultant the UK Government, to the He has in over 25 years experience havingin commercial the and held pharma/biotech drug space, clinical, discovery R&D, Board positions across a diverse range of organizations from multinational pharmas to biotech and pharmaceutical service organizations. He held senior commercial roles at Pharmaceutical Profiles Ltd, Pharsight Corporation and F2G Ltd and led commercial activities at MDS Pharma in Europe. A pharmacist by profession, he holds a degree in a neuropharmacology drug research. and began his career in CNS Pharmacy, Ph.D. in ERA Biotech SA ERA Biotech CEO, A De Smedt, Lieven Lieven A De Smedt is an engineer in Agro and Food industries (WITH MBA (with honors) honors) at KUL- at Leuven, Belgium (‘84-’85) and IHR-RUG, he holds Gent, a Masters Belgium in Finance (cum (‘75-’80) laude) at Tilburg University, and Netherlands (’04-’05). work experience Lieven’s can be At summarized ERA as Biotech follows: SA CEO as: (Feb-11 YTD) – and NED and interim- CEO (2010) At Revolymer Ltd. as: Chief Business Officer (Sept-08 to 2010), CFO and Company Secretary (2005 to Sept-08) and Co- founder (inception in Oct 2005) Founder and Managing Director Jan 2000-Date, ARS.21 BVBA), BVBA (Formerly InnoTune Albemarle Corp (a $2.5 billion Globalchemical Businessand Managerfine chemical (’93-’00) global and company), Market (’89-’93) Pharmaceutical Fine Chemicals Manager, Market manager (‘84-‘89) Tereos), now Tate&Lyle, Amylum NV (became later Market manager (‘82-’84) supplying the food industry), Sopura SA (mid-size chemical company, Managing Partner, Life Sciences, Cukieman & Co. Life Sciences, Managing Partner, Choppe, Laurent Laurent Choppe is leading CLS since 2008 and brings multifunctional teams and setting an up new businesses extensive in nutraceuticals, animal pharmaceuticals, biotechnology, health and international life science experience in managing direct-to-consumer After markets. a veterinary practice and a new venture management experience, he spent 10 years in Schering-Plough in various marketing and general management positions in Israel France, and He Canada. then served as international General Manager of BELLUS Health (ex-Neurochem NASDAQ a TSE), & Canadian biopharmaceutical company disease. Alzheimer’s mainly involved in orphan drugs and Choppe is a Doctor Dr. Veterinary of Medicine of the University Paris laureate XII, of the École Vétérinaire Nationale d’Alfort, CES Veterinary of Ophthalmology and earned a MBA from INSEAD in Fontainebleau He (France). is father married, of 3 and lives in Lausanne (Switzerland). APIM Therapeutics AS Therapeutics APIM CEO, Alevizopoulous, Konstantinos Konstantinos Alevizopoulous has thirteen years experience diagnostic and in medical device products in Since the he 2010, biomedical has sector. served the as the Chief Executive Officer development and commercialization of a AS, Therapeutics APIM venture-capital of financed oncology biotech He (Norway). is therapeutic, also aVentac Partner an Partners, of international business development & Other consulting important corporation. past Chief positions Scientificinclude: Officer (US) Inc. Biovista of D & R Preclinical of Head (GR), SA Medexis of Officer Executive Chief (GR), SA International Gerolymatos of institutes academic companies, biotech several for consults Alevizopoulos Dr. (CH). Corporation Apotech of D & R of Head and and government associations; he is also a co-founder of Casigen Pharma (Hong ZestagenKong), PharmaCellion (CH), (UK) and of the Hellenic Biotechnology Cluster (Greece). Alevizopoulos Dr. received his Biology Athens, Greece degree and from his the Ph.D. in University Molecular Biologyof from Research the Plough Schering University the and (Switzerland) of Research Cancer Experimental Lausanne, of Institute Switzerland. Swiss the He in studies post-doctoral has also conducted Institute (USA) specializing in preclinical oncology research. Alevizopoulos Dr. is trained in France). Schuman University of Strasbourg, European Patent Law (Robert WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Lubor Gaal is the Head of Europe, Search and Evaluation, Strategic Transactions Group for Bristol-Myers Squibb, based at the at based Squibb, Bristol-Myers for Group Transactions Strategic Evaluation, and Search Europe, of Head the is Gaal Lubor companies or assets programs, drug of acquisition and licensing for responsible is He (London). Uxbridge in headquarters UK BioPharma strategy. in support of the company’s Lubor has extensive experience in evaluating and negotiating transactions with small and large companies, having worked in the U.S. and in Europe. Prior to joining Bristol-Myers Squibb, Lubor was Head of Business Development for Neuro3d in France and CBO of Therapeutics Vectron AG in In Germany. the U.S., Lubor worked for Berlex Laboratories, where he was Before AG). HealthCare Bayer (now AG Schering for Neuroscience and Cardiovascular for licensing worldwide for responsible joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical companies on business development strategies and Lubor execution. received his from Ph.D. the University of California at United Kingdom. in Neuroscience from the University of Sussex in Brighton in Berkeley and his B.Sc. Head of Europe, Strategic Transactions Group, BMS Group, Transactions Strategic Head of Europe, Lubor Gaal, CEO, BONESUPPORT CEO, Diamond, Lloyd Heptares Therapeutics Heptares CEO, Director, Founder, Weir, Malcolm Biomolecular the of Head was He London. College, Imperial from biophysics and biochemistry in PhD and BSc a has Malcolm Structure Department and then the Molecular Sciences engaged in target validation Division and lead During discovery. this time of he led the application GlaxoWellcome of structural biology and with modelling responsibility for to drug resulting discovery, in 300 the advancement of clinical candidates people to a wide range of diseases. He joined the structural bioinformatics and drug discovery company Inpharmatica Ltd as CEO in 100-person 2000, company. Inpharmatica growing was it sold from to the Galapagos spin-out NV stagein 2006. to He a joined MRC Technology in establish 2006 Heptares in Therapeutics order to Ltd in same the at JulyBoards Advisory Biology Chemical and Chemistry 2007, the on is as and 1997 in London co-Founder College, Imperial at Biochemistry and CEO. Malcolm was elected Visiting Professor of He served on the Council of the UK Biotechnology and Biological Sciences Research Council from 2004 – 2011. university. Lorenza is a health & biotech equity analyst at Equity Development Ltd. covering private & publicly listed SMEs companies in Europe Prior Australia. and to joining Equity Development in January 2005 she held similar roles at leading international distributing and writing of means by companies and investors together brings Development Equity organisations. investment detailed We research. provide the markets with both facts and opinions along with fair valuations based upon diverse and appropriate Over metrics. the last decade our brand has become synonymous with quality objective research and we have built close links with institutions across the UK and Europe; like them we are fully regulated. Our team of analysts are FSA approved and boast a cumulative 400 years of Please experience. visit for www.equitydevelopment.co.uk more details and examples of our work or contact me. I am the health & biotech analyst and I have many years of experience in the sector having worked for leading international organisations. investment Health & Biotech Equity Analyst, Equity Development Ltd Analyst, Health & Biotech Equity Castellón, Lorenza WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers BioMedPartners AG BioMedPartners General Partner, Markus Hosang, Markus is a General Partner at BioMedPartners AG in Basel, Switzerland. He has strong experience and broad knowledge in strategic and operational aspects of the venture capital business, as well as in product pharmaceutical development research and marketing and areas, with in special many expertise in the areas of biotechnologies, strategic alliances, and Hosang Before was Venture Partner theranostics/diagnostics. a joining at BioMedPartners MPM where in Dr. Capital, 2004, he was co-responsible for their Pharma European the in positions managementdeal senior several held flow,he and years, 20 nearly servedfor where, onBasel, in Roche theat was he boardsPreviously, of several European portfolio companies. R&D organization, Vice including President and Director of Global Pharma Research Strategic Unit and Chief of Staff to the President of Pharma R&D, membership of the Global Board of R&D Directors, Head of Development Projects in Basel and Member of the Roche Portfolio Board, and most recently, as a Deputy Head and Roche Genetics Executive Committee. and a member of the Chief Integrated Medicine, Scientific Officer of Genetics and He obtained his Ph.D. in Biochemistry from the ETH in Zurich and pursued his postgraduateHosang training at Stanford Dr. University dieseases. vascular in Seattle in Washington of University the at subsequently and neurobiology in School Medical served on the Board of Directors and the Board of of Trustees the Swiss Foundation for Stipends in Medicine and Biology (SSMBS) as its from Treasurer 1994-2002. He currently is a member of the boards of Okairos AG, Suppremol GmbH and ViaCell), with merger its (until Kourion Omrix, of boards the on was he Earlier Board). the of AnergisChairman interim (as SA He has published and more Avontec Neuraxo. than 30 articles and in is peer coinventor reviewed on journals, Atugen, IDEA, several patents. immatics biotechnologies Director & Head of Finance, Mark Bleckmann, Following degrees in business administration Mark and Bleckmann philosophy, started his career at where IBM, – over the at position last his In functions. planning and finance various in responsibilities escalating of roles held he – years 9 of course outsourcing contracts largest at the time. IBM he was Finance Manager of the Frankfurt office and one of Europe’s He joined immatics in 2008 where he is responsible for managing all finance matters andas well as other administrative raising €54m. 2010 immatics In successfully round, closed a C financing functions of the company. Martina Kaufmann Strategic Consulting Martina Kaufmann Strategic Managing Director, Martina Kaufmann, solutions individual offering Consulting Strategic Kaufmann Martina of director managing and founder is Kaufmann Martina Dr for personalized medicine. She is a pharmacist with scientific track record in molecular biology and >14 years of hands on experience in personalized medicine from a technology / diagnostic the lifecycle. as well as from a pharmaceutical perspective across Kaufmann has a background inter-divisional comprehensive, with Dr. experience not only in drug development/translational medicine, molecular diagnostics, and molecular imaging, but also in marketing, sales, project management, and business development in biotech start-up as well as global pharmaceutical organizations. She established and implemented consolidated project specificdevelopment biomarkerprojects in / diagnosticexploratory and strategiesfull development, as for variouswell oncology as for marketed She targeted also Herceptin®/HER2. therapies/companion has e.g. diagnostics, experience in molecular imagingmarket adoption and lifecycle management launched successfully and Europe of in system profiling protein based microarray a of entry market enabled development, agent a microarray based pharmacogenetic profiling system. Novartis Venture Funds Venture Novartis Managing Director in Basel, Markus Goebel, Venture Fund Markus Novartis Markus is Goebel Managing started Director, his career in the Health Care Industry in 1990. An MD by training and amongstcertified, inothers, hematology/oncology he worked for Farmitalia Germany and later held several global positions in R&D, Marketing and Strategy at Roche headquarters, partially in a ww alliance with Amgen. He joined Novartis in 2000 and first worked as global head Nervous System BD&L Pharma and later as global head Pharma Corporate M&A. In 2004 he joined the Novartis Venture Fund as a Managing Director in the US. Previously he received an MD and a PhD from the Ludwig University Maximilian’s in Munich FoldRx, and an Sirtris, MBA from from Henleyothers Management amongst College. Markus exited, having companies, portfolio Fund Venture Novartis several of boards the on serves EraGen and Intellikine. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Michael Kotsanis has over 20 years of experience across the experience global pharmaceutical He markets. is the Chief in Commercial Officer for a Synthon, position he the has held pharmaceutical industry and since has Synthon mid is 2010. a fast growing specialty pharmaceutical company The based Netherlands in and is a significantleader in the senior leadership and developing for responsible is he Synthon At countries. 11 in people 1400 over employs Synthon medicines. generic of field mid Until capabilities. R&D and portfolio product class world company’s the leveraging operations business global its expanding 2010, he served as President, Europe, Middle East and Africa for Hospira, where he was responsible for developing strategy, Mayne of acquisition its following Hospira joined Kotsanis region. EMEA the in leadership market attaining and growth delivering commercial Mayne’s leading for responsibility had he 2002 From Asia-Pacific. servedPresident, he as where 2007, in Pharma Mayne joined He of acquisition their following region. Pacific Asia operationstechnical and associatedand the across activities Australia in execution and strategy marketing and sales for responsibility held he where 2001, in Pharmaceuticals Faulding H F Kotsanis began his Prior career to with Faulding, and Boehringer New Ingelheim Zealand. where he held a variety of sales and marketing positions Melbourne over Kotsanis an earned 11 a year bachelor period. of science degree from Monash University, Sydney. Technology, degree in business from the University of and a master’s Lundbeck Ventures Ventures Lundbeck Managing Partner, Agger, Mette Kirstine development business covering science life / biotech within experience international broad a broad a was Agger Kirstine Mette Pharma, 7TM founding to Prior Pharma. 7TM of co-founder and CEO as including financing, and management licensing, and Mette was part of the management team of appointed been has Mette NeuroSearch companies. biotech A/S several co-founded years the over has responsible and Agent Patent as for carrier her started business development and licensing. She to numerous board positions both in private and public companies. Mette Kirstine Agger graduated as Biologist University from of Copenhagen and has the an Mette MBA. Kirstine work as board member including position as board of director in Veloxis. PsiOxus and Allocure, Synthon BV Chief Commerical Officer, Kotsanis, Michael Domain Associates Domain Partner, Vitullo, Nicole Nicole Vitullo joined VentiRx Domain and Pharmaceuticals Marinus Therapeutics, Esperion in Therapeutics, Durata Pharmaceuticals, Celator 1999 Pharmaceuticals, and became a addition In Pharmaceuticals. Partner Onyx and Eunoe Cerexa, Therapeutics, Calixa include memberships in Board Past Pharmaceuticals. 2004. Present board memberships include to investment Achillion responsibilities, she is involved in the distribution/liquidation strategies for the public companies in Domain’s venture capital portfolios. From 2000 to 2011, Ms. Vitullo was responsible for Domain Public Equity focused Trust on Partners a private Biotechnology L.P., investments fund International in of public investments companies. From market 1992-1999, Vitullo Ms. public was Senior U.S. Vice the President for at responsibility Rothschild had she where Inc. Management, Asset Communications Corporate of Director the as served Vitullo Ms. 1991-1992, From Limited. Investments Biotechnology and plc and Investor Relations at Cephalon, a publicly traded biotechnology Prior company. to Cephalon, Vitullo Ms. spent 12 years most recently atin CorporateEastman Kodak, Development where she was involved in the development and management of venture capital activities. Kodak’s Opexa Therapeutics Inc. Therapeutics Opexa President & CEO, Warma, Neil than more has He 2008. June in Inc. Therapeutics, Opexa of Officer Executive Chief and President appointed was Warma Neil Mr. Opexa, joining to Prior Canada. and Europe industrysciences life the in experience U.S., level executive the in of years 19 privately-heldclinical a Inc., Therapeutics Viron of Directors of Board the of member a and CEO & servedPresident as Warma positioned Warma the stage biopharmaceutical company developing a Mr. novel Viron, While class at of protein therapeutics. company as a leader in the treatment of serious inflammatory disorders. an Internet company providing clinical Inc., was co-founder and President of MedExact Warma USA, Mr. Viron, Prior to joining information and services to physicians and pharmaceutical which companies, was ultimately sold to a large public European firm. PriorWarma to held MedExact, Mr. several senior management positions at Novartis Pharmaceuticals at its corporate Switzerland in international policy and advocacy and in global marketing. headquarters in Basel, and an International M.B.A. Toronto obtained an honors degree in neuroscience from the University of specializing Warma Mr. from the Schulich School of Management at York University in Toronto. He Inc. BioHouston, currently serves on the Board of Directors of WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Vaccibody AS Vaccibody CEO, Ole Henrik Brekke, Ole Henrik Brekke M.Sc , Ph.D 1994 from the Institute of Molecular Cell University Biology, of Oslo. Ole Henrik’s work scientific has fostered significant understanding to the function of human antibodies and he isantibody recombinant in patents several on authorinventor the is and ofDiscovery, moreDrug in Reviews Nature and PNAS than Nature, including 20 papers He has technology. been a senior scientist at UiO and National Institute of Public Health and has had R&D director positions Vaccibody in 2008. He was in business development at Birkeland Innovation before joining Affitech and Dynal-Invitrogen. in Inc. Cureline CEO and Scientific Director, Olga Potapova, Olga Potapova is an expert in international alliance Since management. she 2003, is biotechnology, a CEO and Scientific Director life a of Inc., human Cureline, biospecimen sciences business development, biomedical CRO international technology specializing in human development, tissue research strategic projects including for transfer study regulatorydesign, responsible clinical affairs, network is management, Olga and Cureline At logistics. complete and analysis, and collection specimen new products and alliance and Cureline servicesmanagement, expansion is into an new internationaldevelopment, markets. biomedical project management group of companies working in the areas of preclinical and Cureline.com), and translational diagnostic research and (www. laboratory services Previously (www.CurelineBioPathology.com). Potapova Dr. worked in the fields of cancer research (NIA, NIH); human molecular geneticsmedicine and(SUGEN/Pfizer). genomics; Olga oncology has received drug multiple R&D AACR/AFLAC and awards, NIH translational and NATO fellowships, Genetics/ and Molecular in and (M.Sc.) Physics degrees in advanced has She journals. peer-reviewed papers in hasscientific multiple published Biochemistry (Ph.D.). Global Head Business Development and Licensing Respiratory, Boehringer Ingelheim Global Head Business Development and Licensing Respiratory, Paola Casarosa, Paola Casarosa received a master degree in medicinal chemistry and at a the Italy, Ph.D. in University molecular of Torino, Organon joined she Paris, in Hospital Bichat at experience Post-Doc a After Amsterdam. in Universiteit Vrije at pharmacology, working been has Paola 2007 Since Arthritis. Reumathoid of area therapeutic the in laboratoryhead as Plough, Schering NV/ where she in covered Boehringer differentIngelheim, positions within Research and Development for respiratory indications Recently Diseases. Respiratoryfor Licensing of head global as group, Licensing & Development Business the within then and she took over additional responsibilities in the area of PM Strategy and Portfolio-management. Dr Ora Dar is the Head of the Life Sciences Sector at the Office ofTrade the Chief Scientist at the Israeli Ministry of Industry, and the & Consultant Labor, for Biotechnology to the Chief Being Scientist. Dar the leads head the Dr. of team the of sector, experts recommending the granting of financial support by the Chief Scientistto projects inDar is thealso responsible for fielddefining and implementing of tools and Life new programsDr. required Sciences. for supporting R&D in Life Sciences and forcompanies, enhancing the This technology has transfer lead Academia between to and the the the initiation Industry. and maturation of several viable programsfunding academic dedicatedsuch applied as, scheme research, for biotechnology incubator(s), tracks enabling collaboration with global Life Sciences companies, tools for Institute Weizmann upgrading foreign the at(mostly research academic in years 16 spent she Previously as Funds. Bio backed government special infrastructures, well as and firms investment a and capital venture to consultant a as years 10 and industry, the in years several Science), of funds and international R&D programs. Dar Dr. is a medical sciences graduate of the Hebrew University of Jerusalem holds and a from Ph.D. the University Hospital of UK Mary’s Medical Imperial Technology London, (St. School, College of Science, and Medicine). Head of the Life Sciences Sector, Office of the Chief Scientist, Office of the Chief Scientist, Head of the Life Sciences Sector, Dar, Ora Israel and Labor, Trade Ministry of Industry, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Dr Philippe Calais is Chief Executive Officer of Antisense Pharma since March 1, 2012. He has over 25 years of biopharmaceutical Antisense Pharma GmbH of CEO, Philippe Calais, years 25 over has He 2012. 1, March since Pharma Antisense of Officer Executive Chief is Calais Philippe Dr and pharmaceutical industry experience in both North America and Europe. Prior to joining Antisense Pharma, he was the President and CEO of the Univalor, largest technology transfer strategicorganization corporate on located focusing in companies, science life Montreal, to Canada. consultant He a as servedhas and Canada managed in companies biopharmaceutical positioning, company deployment and sales optimization strategies. His management expertise, combined experience with large pharma with companies such as ICI extensive Pharmaceuticals and covers Roche, the full scope of the drug chain – several for marketing strategic franchise and partnership as well as commercialization development, clinical discoveryto from France. Tours, Rabelais, F. He has a degree and doctorate in pharmacy from the U. therapeutic areas. EVA the Basel Life Sciences Start-up agency EVA CEO, Peter E. Burckhardt, Peter plays an important role in supporting innovation in Northwestern His Switzerland. main focus is life sciences start-ups. Peter is CEO the “EVA of Basel Life Sciences This Start-up company agency”. was founded in 1996 with the aim to support life sciences start-ups access with to coaching, a high value In network addition and he providing is seed CEO money. of the which BASEL he INCUBATOR, helped to establish 2 years The ago. BASEL is INCUBATOR a joint venture of the University of complement To Applied Sciences of the Northwestern University Switzerland of (FHNW) and the Canton Basel, of Basel-Stadt. focusing Switzerland in Club Angel’s Business only the Club, Angel Business BioValley the of president the is Peter activities, his Novartis / Ciba-Geigy joined and Basel of University the chemistryfrom in PhD a has Peter MedTech. / sciences life on entirely Throughout his professional career he had managerial positions with worldwide responsibility in 1984 as a research chemist. technical regulatorydevelopment, production manufacturing, affairs, and communication and was the CEO of the subsidiary in 2006. He joined EVA of a sector of Novartis in Germany. Head, Johnson and Johnson Innovation – London, Johnson and Johnson Johnson and Johnson Innovation – London, Head, Verheyen, Patrick Patrick Verheyen is Head of the the in businesses Johnson & Johnson Johnson to products and technology science, early-stage on-boarding & and fostering identifying, Johnson Innovation Center in London – a Consumer and MD&D sectors. Pharmaceutical, new organization dedicated to Patrick was most Ventures within Vice New recently Janssen President, Pharmaceutical Companies of Johnson & Johnson. In this he role, led a nimble and diverse team that facilitated established divestitures, strategic collaborations and identified investments that provided Janssen with access to external innovation and Priorearly toproduct Patrick Vice that, flow. was President, Mergers & Acquisitions within the Pharmaceuticals Group. In this role, Patrick facilitated strategic collaborations and acquisitions including Elan Crucell, and and established Cougar based Movetis, a Biotechnology, on spin-out company, the in deals M&A major the of most on expertise provided has Patrick portfolio. pipeline gastrointestinal Johnson’s & Johnson biotech, specialty pharmaceutical and large cap space, and assessed various risk sharing and funding arrangements with private equity and government institutions. Clinical Research Organizations (CROs), he Patrick In relocated joined 1996, Belgium. to Johnson in the & Beerse, Johnson in 1985 at Janssen Pharmaceutica N.V. USA Business as Development, Director, Pharmaceuticals Group, and in 1997, was promoted to Vice President, Corporate Belgium. He studied bio-engineering at the University of Leuven, Ortho-McNeil Pharmaceutical. Development, Les Laboratories Servier Les Laboratories Operation Director – Scientific BD, & Touchon, Pascal Pascal Touchon has 26 years’ experience in Management Development. and Business the pharmaceutical industry in Research, Marketing and Sales, He General has extensive international experience in managing commercial operations Africa. and South and Canada, Australia, as Asia, CEO Northern Europe, Europe, in France, Central & Eastern As head of Business Development for Servier over the last 3 years, he led the closing of more managed alliances and conducted two company various existing than acquisitions. institutes, biotech companies and academic 18 partnerships with Servier is a private research based pharmaceutical company rheumatology oncology. and psychiatry, with neurology, type II diabetes, cardiovascular diseases, sales of 3.9 billion euros worldwide and activities in a DESS in Management and an MBA from INSEAD. Veterinary Medicine, Pascal holds a Doctorate in WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Biomay AG Biomay CEO, Rainer Henning, of career distinguished a on back looks He 2011. January since AG Biomay of Officer Executive Chief as serves Henning Rainer Executive Chief was he Biomay, joining Before industry. capital venture and pharmaceutical biotechnology, the in years 30 over after over took he a position medicine, care critical of field the in company biopharmaceutical a Inc., Medical, Fibrex of Officer working as investment manager and partner of two European venture capital funds for Roussel several Marion Hoechst years. His AG, experience in Hoechst in the positions R&D executive senior and operational encompasses industry pharmaceutical and Aventis. A chemist by training, he is inventor of over 80 granted patents, advised and served he has number of biotechnology on the board of a companies. In addition, which antihypertensive ramipril. cover among others the blockbuster Juventas Therapeutics, Inc. Therapeutics, Juventas CEO, Aras, Rahul He is also a(President co-founderand Chief Executive ofOfficer) SironRX is the founding CEO for Juventas. Aras Ph.D. Rahul Therapeutics, a company focused on novel regenerative therapies in the dermal and cosmetic fields.than $35 million in Heventure capital and grant funding to transition both companies hasfrom concept into mid-stage clinical trials. raised more Prior to Juventas, Rahul was the Director of Life Science Commercialization at Cleveland Clinic Innovations (CCI) where he is managed commercialization of all biotechnology and pharmaceutical related technologies. He research has held has extensive He negotiating licensing deals and strategicexperience partnerships ranging from top 10 pharmaceutical University. companies to newly formed start- York New from research biomedical in Ph.D. a and University Tufts from B.S. a received He ups. positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. CEO, Scancell Holdings Plc. CEO, Goodfellow, Richard companies. Biotech with and Pharma Big in industry, pharmaceutical the in experience international years 30 over has Richard of post the held he Thereafter, internationally. products key other and Losec of launch the oversaw he Astra, at time his During Director of Licensing and New Business Development at where Scotia he Pharmaceuticals, was involved with the company’s flotation on the London Stock Exchange and successfully negotiated numerous deals. Paradigm of co-founder a also was Goodfellow Dr business, vaccine cancer ImmunoBody Scancell’s co-founding to addition In a Cambridge based functional genomics company and was a former Director of Enact Pharma plc. Therapeutics, Regina Hodits joined Wellington Partners in spring of 2010 as General Partner for Wellington Life Science. With over 12 years 12 over With Science. Life Wellington for Partner General as 2010 of spring in Partners Wellington joined Hodits Regina of investing experience and a strong scientific she background, has become an influential investor in the European venture focusing on early-stage and growth deals in Life Sciences. capital scene, Philips’ the creating in instrumental was UK; Oxford, Oxagen, in investment the managed has Regina Wellington, joining Since Ayoxxa’s foundedSingaporeestablish to helped and Netherlands; the Eindhoven, and Germany Munich, in Sapiens, spin-out presence in In Cologne, Germany. addition, Regina serves as an external Board member for the GSK’s respiratory therapy area unit (TAU). Prior to joining the Wellington team, Regina led the life sciences efforts of Atlas Venture in Europe, a leading transatlantic venture capital firm. As amerger Partnervia NASDAQ aton (public Atlas,Novamed she Egalet, of ledBoard the numerouson served she financing Furthermore, roundsJenavalve. and andF-star Therapeutics, was the founding investor in Bicycle in 2008. by which was acquired Daiichi Sankyo Co.,Ltd. with SCLN) and U3 Pharma, From 2000 to 2004, while working for Apax Partners, Therapeutics University she and the Wilex. at She researcher was post-doctoral began and to lecturer closely university build a her involved as worked extensive Regina with network 90s, in the investments In the global 2000. in to healthcare 1997 industryfrom Genmab, McKinsey during Silence her tenure at in biochemistry. Regina studied chemical engineering and holds a Ph.D. UK. Austria and the MRC Cambridge, Vienna, of Wellington Partners Wellington General Partner, Regina Hodits, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers President & CEO, Insuline-Medical Ltd President & CEO, Ron Nager, Helsinn Healthcare SA Helsinn Healthcare Corporate Business Development, Senior Director, Roberto De Ponti, Roberto De Ponti a Pharmacist by training and an EU Qualified Person, started his career in pharmaceutical analysis in the former Farmitalia Carlo Erba, followed by formulation and drug development. His responsibilities grew went an while impressive series of M&As (from the Farmitalia Carlo Erba to company Kabi Pharmacia Pharmacia, & Pharmacia Upjohn, with the merge with and Searle, eventually gettingPfizer), site responsibilities for drug substance anddrug product development and (specialized Pharmacia of site Italian R&D the of lead site also was He products. marketed and investigational of manufacturing in Oncology) and eventually followed the transition to Pfizer and also(Nerviano where Medical he Sciences), became responsible for thethe Pharmaceutical Science section bringing it to transitionbreak even to an independent spin-out company offering development services to oncology companies wordwide. During his career De Dr. Ponti was instrumental in the development of many oncology drugs, including new formulation of anthracyclins and sunitinib with andPharmacia/Pfizer, a variety of other oncology projects working as consultant to several Under on his companies. a direction, yearly basis he was responsible for investigational supplies to more than 8000 patients Corporate of Head is he 2008 Since year. per units drug oncological of units Million 50 of production market for and worldwide, Business a Development privatelywith Helsinn, owned pharmaceutical group with headquarters and in Lugano (Switzerland), China. and a representative in Beijing, office United States, Ireland, operating units in Biasca (Switzerland), products supplement nutritional and devices medical pharmaceuticals, of licensing the on focused is model business Helsinn’s in therapeutic niche areas. Care Supportive Cancer of areas the in mainly projects R&D of research external include responsibilities current Ponti’s De Dr. and Therapeutics Cancer focusing on Phase II completed and programs, execute the due diligence and negotiation activities for in-licensing products. In the last four years he was instrumental to the acquisition of two oncology related development products programs of portfoliofor a and Helsinn, addition, In year. current the during concluded positively be to expected are negotiations advanced other filling the integrative medicine needs in oncology has been implemented. Dr Ron Laufer is the head and Senior Managing Director of MedImmune Ventures, a $400M evergreen venture capital fund. a $400M evergreen venture capital fund. Ventures, Dr Ron Laufer is the head and Senior Managing Director of MedImmune start-up IT Healthcare and MedTech BiopParmaceutical, in invests Group, AstraZeneca the subsidiary of a is which fund, The Australia. Israel and Europe, America, companies in North An experienced healthcare Ron investor, started his career as a physician before moving co-founder into of Lilly the Ventures, venture venture capital capital. arm of He Eli Lilly was & and Company, later a a Managing Director at Visium Asset Ventures in 2010. before joining MedImmune a private healthcare-focused investment firm, Management, Ron received his from B.Sci., M.D. and Hebrew and M.P.H. University, an M.B.A. from the Harvard Business School. He is currently an adjunct Professor of business administration at the Kelley Business School of Indiana University Medimmune Ventures Medimmune Senior Managing Director, Ron Laufer, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Vice-President of Strategic Development, AKRIKHIN OJSC Vice-President of Strategic Development, Rustam Ixanov, Academy. In 1996 graduated from State Medical Russia. Rustam Ixanov was born in 1973 in Nizhniy Novgorod, Rustam began his career in pharmaceutical business as Group(1999-2000). a STADA «Nizhpharm», manager of medical information in pharmaceutical company From 2000 till 2002 he was a Head of 2002-2006). Group, STADA Medical («Nizhpharm», department of «Nizhpharm», STADA Group. Later he was R&D Director Before «AKRIKHIN» Rustam was a Development Portfolio Director of pharmaceutical of this company).Pharmaceuticals is the most significant investor company ”Izvarino Pharma” (Ferring From September 2010 he has been the Vice-president of strategic development at “AKRIKHIN” OJSC with for: responsibilities Strategic Portfolio Development, Product Development, Business Development, Intellectual RegulatoryProperty, Affairs, Pharmacovigilance. Preclinical/Clinical trials, Life Sciences Advisory LLC Life Sciences Managing Partner, Ramasastry, Saira Saira Managing Ramasastry, Partner of Life is Sciences Advisory, a seasoned industry insider with approximately 15 years Lynch Merrill atcoverage biotech emerging led Saira LSA, to Prior transactions. 80 over on advised has who and experience for over a decade where she helped establish Saira the Prior leading to life Street. Merrill sciences Wall Lynch, franchise on Perella. Wasserstein worked in M&A and Restructuring at Saira is a recognized thought leader on public-private alliances and is frequently called upon as She a servesspeaker. on the Industry Advisory Board of the Michael J Fox Foundation for Parkinson’s Research, Advisor to the California Institute for Regenerative Medicine. Foundation and as a Special the Board of the American Liver Saira has a B.A. in Economics with Honors and Distinction from Stanford University where she graduated Phi Beta Kappa, and advanced degrees in Management Science & Engineering and Management Studies from Stanford University and the University of Cambridge. She currently serves on the Advisory Council for the Cambridge Judge Business School and was 40 under 40 list . Jose Business Journal’s Valley/San recently named to the Silicon Ennar Pharma AG Ennar Pharma CEO, Rudi Neirinckx, more and publications scientific 100 over of author and industryexecutive pharmaceutical experienced an is Neirinckx D Rudi licensing, development, clinical research, i.e. business, pharmaceutical the of aspects most in worked He patents. dozen a than in the diagnostic as He well also as was the a therapeuticetc. consultant forside of the the business. business development, Space Shuttle program. NASA’s After an academic career in Nuclear Medicine producing and radioisotopes radiology, with a cyclotron and developing novel radiodiagnostic products, he headed up the R&D operations including of deals, Amersham M&A and International license numerous (UK) made he and where KGaA, Serono Merck of (Geneva). Department He M&A the was reorganizing for responsible a major license deal He with foundedImclone Systems. an based OTC on Company Belgium), his (Agys invention Pharma, of helped he which USA), Pharmaceuticals, (PAR Company Generics a of COO was and sensitivity dental of treatment effective an He turn also around. was CEO of a atugen, Berlin beforehigh-tech start-up, he became a full-time consultant in Oncology to and of property now is which project, psoriasis the on worked exclusively has he Subsequently Pharma. Altana of President the AG. developed by Ennar Pharma WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Katan Associates Katan Chaiman & Co-Founder, Yakatan, Stan After 30 years as a and has Stan Yakatan successful operational dedicated CEO, entrepreneur, manager, the last 12 years of his career to sharing his experiences with management teams interested in building technology based companies. His level executive is far reaching he has served in such a capacity with: “C” experience as a New England Nuclear • EI Dupont • ICN Pharma • New Brunswick Scientific • Biosearch These experiences have provided him with management skills and a corporate finance acumen that he enjoys sharing with others. Stan has founded or co-founded in excess of 15 companies in the of several United advised has he States, Canada, Israel, France career, and his In In Germany. companies. these of Chairman and CEO, initial the servedas also has he cases many During (Canada). Biocapital and (USA), MSP (USA), Ventana (Germany), TVM including firms capital venture leading world’s the Biocapital was the most successful venture capital fund in Canada. the decade of the 1990’s systematically Group Tech XL The XLT). (AIM: TechGroup XL the for capacity development business a servesin currently Stan liquidity. to them scales and businesses, technology new develops and selects, creates, then needs, business unmet discovers XL for strategy capitalization overall the on advised and model, business its of development the in TechGroup XL assisted Stan Alternative the on listing its with connection in Offering Public Initial an undertook TechGroup XL 2004, October In Group. Tech $40.0 million. raising in excess of Investment Market (“AIM”), Stan has completed and advised on numerous acquisitions and corporate finance transactions raising inbillion excessdollars in ofthe $1.0 public “The and and private Start-Up” capital Technology-Based financingthe markets.for HeRaising “Capital is aincluding, topics frequenton speakerspeaking world atthe throughout financialconferences and biotechnology Need to be Global Yakatan in the Quest for Capital Editor Rick and of Biondi, Partners”. Lab Mr. Business Magazine stated,” is a venture capital raising Guru and it is part of his genetic make up.” Stan is currently the Chairman of Grant (OTCBB:GLIF) Life Inc., a Sciences, company developing a revolutionary test for the Stan screening is of also cervicala member cancer. of the Board of Stan Directors (OTC.BB). servesof Inc. Biophan, as the Biocomm, of Chairman and Director Executive the also is Stan Australia. Victoria, of Government State the to advisor strategic currently Stan pool. capital early-stage and agency development business regional kind its of first the Australia, Melbourne, in and Phenomenome which is developing new sits drugs Inc. on for the diabetes Board Therapeutics, of and Mercuryobesity, a novel biomarker company. Inc., Discoveries, Novo A/S Novo Managing Investment Director, Moller, Søren Søren obtained his MSc degree from University the Technical of Denmark in 1993 and his PhD degree in molecular biology in 1997 University from of Technical the Denmark for a project on In molecular addition microbiology. to his Søren PhD, has academic training as postdoctoral fellow at Stanford University School of Medicine. Prior to joining Novo microRNA of development for Seeds, responsible was he where A/S Exiqon at R&D Søren of President Vice and CSO was Søren Novozymes, served as global manager of Bioinformatics based products and for life science Genomics research, pharma services atand diagnostics. In 2007 Novozymes. Exiqon completed an Before IPO on NASDAQ Søren OMX Copenhagen raising 400 mio DKK to develop and Previously, commercialize life science and diagnostic products. Identificationworked in cancer drug development as head of Lead at BioImage and as research scientist at Novo Nordisk. Søren Denmark). in Industries Biotechnology of Association (the Biotech Danish of member board been has Søren 2008, Since a Swedish based biotech company. AB, serves on the board of directors of Denator Roche Partnering Roche Strategic Partnering, Global Head, Holland, Sarah Sarah Holland is the Global head, projects Strategicinclude broad strategic landscapes Partnering of M&A and late forstage opportunities, transactional support for Roche all pharma M&A Partnering based initiatives transactions, to generate income through spin-outs divestments, and strategic in and partnerships, development and Basel, Switzerland. Her team’s danoprevir to rights world-wide acquired team the 2010 In needs. business key address to structures deal creative deliveryof from Intermune and supported the acquisition of Marcadia Biotech. Since joining Roche responsibilities in in business such development, as Global 2005, Head of CNS Sarah and Partnering, has led projects in has a range of disease held various deal on b-raf inhibitors. including the Plexxikon areas, Prior to joining Roche, Sarah was Global Brand Director at AstraZeneca for a hormonal agent for breast She and held EU various launch. commercial and strategiccancer roles over her including ten Global years Strategicthere, during Planning US Manager for early Pricing compounds, Strategist she and AstraZeneca, held Health Before local Economist. and international biotech and pharmaceutical companies. sales and marketing roles in diagnostics, first and D.Phil her and 2004, until Fellow Visiting a was she where School, Business Manchester from MBA her gained Sarah degree at Oxford University. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers COO, i-Optics COO, Elzakker, Thomas van Thomas van Elzakker joined i-Optics in July 2012 as COO with responsibilities marketing in positions held he where for Healthcare, Philips with years followed16 i-Optics to move His operations. supplychain R&D, product management and global Thomas 2005, December to 2000 November From organizations. field and units business various in management general and lived and worked in the USA and was the global Healthcare, Philips Servicesof marketing Global organization the in Ventures New and forManager General was he strategy recently, More executive Radiology. for the Philips CT scanner business in building a successful new professional services venture. Thomas holds an MSc in Applied Computer Science from University in the Netherlands.. Leiden Colby Pharmaceutical SAB Colby CoChair, Thomas Kündig, completed Kündig Dr. Zinkernagel. Rolf Dr. with together lymphocytes T cytotoxic of biology the on studies pioneered Kündig Dr. medical school at the University of Zurich in 1987 and went on to earn a medial thesis in respiratoryalso at physiology, the University of Enrolled Zurich. in the postgraduate course for he experimental studied medicine immunology and as biology, a post-doctoral fellow in the laboratory of Nobel laureate Professor Zinkernagel, where his work began on understanding how immune responses are stimulated and maintained. Department the in Mak Tak Dr. and Ohashi Pamela Dr. with immunology and biology molecular in trained Kündig 1992-95 From Since of 1995 Medical he Biophysics has atworked as the a Princess clinical Margret Toronto. dermatologistHospital in and allergologist/clinical immunologist at the University Hospital in Zurich, where his research group specializes in allergen and cancer immunotherapy. Kündig Dr. has published numerous scientific papers in leading journals such as Nature, Science, Cellcumulative andcitations >11’000 Immunityand an with h-index of 47. He has received several fellowships from the Swiss National Research Foundation and the Cancer League. Since 1998 Dr. Kündig lectures University in of dermatology, allergology Zurich. and He immunology was at given the the Georg Friedrich nominated in 2000 by the Ludwig Institute for Cancer Research as an affiliate researcher. Götz Award for outstanding medical clinics, dermatology outpatient the research for responsible is and in supervises he where 1999, clinics, the in and time his of 50% was spends Kündig Dr. hair diseases, autoimmune for unit unit, oncology unit, Laser unit, therapy UV unit, radiotherapy dermatology, general including and unit, emergency dermatology the diseases, skin inflammatory for center the unit, allergy unit, testing epicutaneous clinics, the unit for sexually transmitted diseases. laboratory the Overall Department. Dermatology the of laboratories routine the and research of head the is currently Kündig Dr. translational on focuses one third technical staff and two third academics. with approx. and 50 employees, and research department has a size of approx. MDs 3 and students, PhD 2 docs, post PhD 2 of consists currently group research own Kündig’s Dr. research. His research group develops products and strategies taking them from models basic and finallyimmunology intoto the As clinics. preclinical translation into animal the clinics requires extensive regulatory work, toxicology studies and funding for GMP production, the research group closely collaborates with When the developing industry. products for which no industrial partners can be Kündig found, Dr. was and still is also involved in founding spin-off companies as vehicles research to group is Kündig’s certified by the Swissfund Medical further SocietyDr. clinical asdevelopment. a teaching site for numerous performingcurrently is he trials clinical for center verythe In collaborationwith close development. pharmaceutical allergy and dermatology. phase I and II studies in immunotherapy, Torreya Partners Torreya Advisor, Senior Stephanie Léouzon, advisory a life sciences boutique. Partners, Torreya atAdvisor Stephanie is a Senior She has worked in Health Care Investment Banking since 1989, participating in over 65 transactions in the biotechnology, pharmaceutical sectors. pharmaceutical and speciality She has advised clients on a number of strategic transactions, valued provide over $7 billion to healthcare clients. financing transactions to at over $70 billion, and she has been Morgan involved JP Brothers, in Lehman at Care Health in working included experience Stephanie’s 1998, in Suisse Credit joining to Prior and Salomon Brothers (now Stephanie Citigroup). earned an degree M.B.A. from the Darden Graduate School of Business at from Mount Holyoke College in 1985. cum laude, degree, Virginia in 1989 and a B.A. the University of WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Director Healthcare Investment Banking, Citi Group. Director Healthcare Investment Banking, Thomas Stockman, Thomas Stockman is a Director in the Global Healthcare Group. investment banking experience. He joined Citi in 2002 and has increase its more on GSK advising including than sectors, services healthcare 10 and biopharma the in years companies many with worked of has He in ownership of GSK Consumer Nigeria, Nabriva on its option agreement pursuant to sale with Forest on Laboratories, its Roche acquisition of Anadys, Hikma on its acquisition of Promopharm, sale Solvay the on on BUPA the Euromedic, in sale stake a of of acquisition its on its Montagu CVCI, pharmaceutical to stake 38% business a of sale to the on Huvepharma Abbott, of its hospitals to Numico Cinven, on its sale to Savient Danone, Pharmaceuticals on the sale of Rosemont to Close Brothers KPC Privateon the Equity, sale of its stake Aventis in to SanteSanofi-Synthelabo, Vivendi Luxembourg ABN) and (Cinven, on financing bonds; KGaA’s Merck and Bayer AstraZeneca, Roche, Holdings; Sante to Sante de General in stake its of disposal the EQT and Investor’s LBO of Gambro, Hikma’s UK IPO and subsequent AEO. He also worked on the Halfords IPO in the retail sector. Thomas has a degree in Biological Sciences from Oxford University. VP SPBD Oncology & STL, AstraZeneca VP SPBD Oncology & STL, Herpin, Timothy CNS for initially Development, Business and Partnering Strategic Vice-President, as 2011 in AstraZeneca joined Herpin Timothy he leads a team of business development professionals involved in In this role, & Pain and more recently for Oncology & STL. development business the in years eight spent Tim AstraZeneca, to Prior franchise. Oncology the for making deal of aspects all disease organizationmultiple in execution atevaluationtransaction Squibband as Bristol-Myers search well as both covering Tim worked Before areas. in his R&D business Tim at development Aventis and Bristol-Myers career, Pharmacopeia. Squibb, University from chemistry organic in Ph.D. a holds also He France. in Polytechnique Ecole of graduate a is and Paris in up grew Stern. College London and an MBA in Finance from NYU Corp. Therapies Biotie President & CEO, Veromma, Timo (Finland; AG Schering Director, Medical 1998-2005; R&D President, Vice 2005, May from CEO and President Veromma, Timo 1996-1998); Program Director at Collagen Corporation (California, USA, 1994-1996); Postdoc Fellow at Stanford University 1990-1993). USA, (California, Finnish Chairman Bioindustries, of the Chairman Board. of the Steering Committee for a HealthBIO, national cluster program focusing on Chemical health Industryapplications Federation of Member biotechnology. of of Finland, the Board of Directors. Member of the Board of Directors. Hermo Pharma Ltd, Epigenomics AG Epigenomics CFO, Taapken, Thomas is acting Taapken as Thomas Dr sole member of the Executive Board of the AG Epigenomics since September He 2012. 30, joined Epigenomics April on 2011 1, as Chief Financial Officer from Therapies Biotie where (Finland), he held the position of followingbusiness a 2008, in position this appointedto was He Team. Management Executive the of member a was and CFO combination between Biotie Therapies and where Thomas elbion had NV, been CFO since 2005. His extensive international experience in the life sciences industry includes previous positions as Investment Partner at DVC Deutsche Venture Capital from 2003 to 2005 and San Francisco-based US venture capital firm areas Burrill &Company the from 1998 He – in also 2002. worked as well as activities, capital venture corporate managing Germany, and U.S.A. the in Sanofi-Aventis at years several of corporate & business development and Throughout research. his he career, has been involved in numerous transactions as well as private and public offerings. divestitures, mergers, spanning acquisitions, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Since 2008 works at R-Pharm as Director for Business Development, then CEO. the 5 international pharmaceutical years company AstraZeneca in the at positions of Sales the Marketing and Director, Marketing Squibb Russian Director, Bristol-Myers company headquarters pharmaceutical international the of of headquarters Russian the at years 7 Director. Sales National in In the 1998-1999 Marketing positions spent Director. Franchise of 7 Manager, Product months Manager, on secondment Sechenov Moscow honors, with diploma – MD NJ. Princeton, in headquarters corporate BMS of group marketing global the at NY)). York, (NeySurgeons and Physicians atof courses College elective University Columbia months 6 Academy(incl. Medical MBA – Academy of Medical Sciences. Academy & Russian PhD – Moscow Sechenov Medical Major in clinical pharmacology. University. Moscow MIRBIS business school & London Guildhall Co-Founder & CEO,, Pontifax Corp. Co-Founder & CEO,, Kariv, Tomer Tomer Kariv is the co-founder and Chief Executive Officer of Pontifax, a group of Israeli based lifefocusing on investments in Kariv development serves sciencesstage as bio-pharmaceutical an and active med-tech Mr. venturetechnologies. funds a special responsibility for assuming strategic planning. board member of many of the funds’ portfolio companies, Therapeutics Arno Ltd, Macrocure of member board a is and Ltd Check-Cap of Chairman the as serves Kariv Mr. others, Among Aposense and Inc. During Ltd. the 10 years prior Kariv to played establishing a Mr. Pontifax, key role in managinginvesting, and nurturing technology driven companies and startups and has held senior management positions at top Israeli financial Kariv institutions. practiced Mr. law with Sullivan & Cromwell, a leading corporate law firm inYork, and New holds a B.A. in from Harvard LawEconomics from Harvard School. University and a J.D. R-Pharm CEO,, Ignatiev, Vasily CEO, Anergis CEO, Vincent Charlon, Vincent Charlon joined Anergis in January 2009 as Chief Executive Officer (CEO), bringing over 20 yearsdevelopment ofand globalmanagement clinical experience. From 1990 to 1998, at Hoffmann La Roche in Basel and then Vincent in USA, Nutley, Charlon held clinical development responsibilities for several international projects. Charlon was CEO From of Hesperion the Ltd., contract research 1998 organization (CRO) who designed to and conducted all initial 2006, clinical Vincent trials for Actelion’s [SWX, ATLN] products. In this Vincent capacity, Charlon designed the first clinical trialsTracleer® of in pulmonary biggest hypertension, today Actelion’s product with sales well over Vincent CHF Charlon 1 developed billion/year. American North and European mostly clients, hundred a over serving employees 200 to 3 from CRO profitable a into Hesperion biotechs. In Vincent 2007-2008, Charlon was CEO of the drug repositioning start-up company LS Pharma International SA A financing of CHF 18 M early 2011. Anergis where he led the round before joining CEO, Lipopharma CEO, Tur, Vincenç Confederation the at and Ibiza) of (Bank institution financial a in been has career professional previous his training, by Economist of Industries in the into Balearic as Islands During chief (CAEB), his economist. 20 innovation years at CAEB he has drive been a reputed regional to initiatives promoting and projects research managing in experience significant gained has and economist several of start-up the in involved directly been also has He implantation. international strong with companies regional leading As co-funder companies. Technology-based of since Lipopharma, 2006 he has significantly contributed to the consolidation signed negotiatedand has he CEO Lipopharma’s As company. biopharmaceutical global sound a spin-offinto academic an of to related patents (three Islands Balearic the of University the with agreements in-licensing 3 including deals, licensing several Toledo in Hospital General Paraplejic the with deal in-licensing one lipids), modified other Minervaland of indications oncology (for Spinal Cord injury and Pain program) and one out-licensing deal AB-Therapeuticswith Ability (now Pharmaceuticals) for cancer indications of a family of synthetic lipids protected by a patent filed by Lipopharma in October 2009. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Speakers Co-Founder & CEO, TN LLC Co-Founder & CEO, Vladimir Kovalskiy, Vladimir is a Computer Science graduate born in the family of Medical doctors. environment he was grown in influenced his vision and passion for the healthy lifestyle. He started company together with his partner Dmitry Lazutkin back in 2008. In course of 5 years Medesk solution was developed with the idea to integrate all players of the healthcare market and provide the better care for patients. He is an avid supported of digital healthcare adoption. Looking for the technology to help more people in getting access to medical treatment diagnostics. and English and Japanese. Speaks Russian, Vladimir has relative working in Japan. experience . WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Director, Finance & Administration Finance & Director, Ruz, Vanessa BEc/MEc in Economics. SL. Chief Financial Officer of Sevibe Cells, Ability pharma years she was the Prior to PhD in Cell Biology & Business Training. 13 yrs in BDL at Almirall & Lacer. 2.5 yrs in biotech venture capital (Barcelona Emprèn Almirall & Lacer. 13 yrs in BDL at Training. PhD in Cell Biology & Business BS/MS Biology. York). incl.2 yrs at Sloan-Kettering Cancer Center (New Memorial 8 yrs in science research, and CIDEM). VP Research & Development PhD, Alfón, José team leader drug 8 yrs, SA. leader drug development (pre-clinical and clinical) at the biotech Palau Pharma, Team 4 yrs. and of Jerusalem Research at Hebrew Univ. PhD in Pharmacology , SA. discovery at the pharmaceutical company Uriach, BS/MS Pharmacology. Universitat de Barcelona. Pharmaceuticals Ability www.abilitypharma.com PROFILE COMPANY The company is 2009. SL is a biopharmaceutical company founded on November 28, Ability Pharmaceuticals, campus. Autonomous University of Barcelona on the based in Bellaterra (Barcelona), which is highly The company a patented is developing , new drugs class called Lipid Analogue Therapeutics Abilitpy Pharmaceuticals currently has two candidates differentiated an innovative and has mechanism of action. to move into phase development and is expected which is finishing preclinical , ABTL0812 in development: and of 2013, and pancreatic cancer in the second quarter trials for lung First in Man clinical Ib, 2013. to start preclinical development in spring which is expected ABTL1014, It was selected for ABTL0812 is an antiproliferativedrug with a novel mechanism of action (MoA). and cytotoxic lymphatic, pancreatic, a) its activity over a wide panel of tumor cell lines (lung, preclinical development because, low in vivo toxicity; and d) melanoma and glioma); b) its good efficacy in animal models of cancer; c) its liver, it shows synergistic properties with standard of care (SOC) drugs Importantly, once dayly oral administration. such as docetaxel and gemcitabine. and thereby proliferation with of ABTL0812 affects two major cell processes related with cellular division, and b) DNA synthesis a) inhibition of akt phosphorylation and mTORC1 and mTORC2 pathways, tumor cells: The modulation main cellular of these through the inhibition of dihydrofolate (DHFR) gene expression. reductase a mechanism of self-digestion of the cell. functions induces cell death by autophagy, MANAGEMENT Chief Executive Officer - Co-founder. PhD, Carles Domènech, YEAR FOUNDED 2009 EMAIL [email protected] TELEPHONE + 34 93 586 8977 ADDRESS Edifici Eureka – Campus de la UAB 08193 Bellaterra (Barcelona Catalonia Spain CONTACT PhD Carles Domènech, Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u FINANCIAL SUMMARY FINANCIAL SUMMARY 2011 Balance 320k€ PROFILE COMPANY forantibodies in the conception and production of chimeric B Cell Design is specialized clinical diagnosis and B Cell Design IgM and IgE. IgA1, immunotherapy basis of patented on the IgG1, KI mouse models producing secretoryhaving the capacity is also available. IgA1 of producing human secretory piece, The main application of the secretory treatment IgA1 is the direct mucosal it’s including the oral route due to Specific IgEs will have a major place in allegro-oncology. exceptional resistance to local proteases. in mice forPre-clinical phase has started in vitro and in vivo secretory dimeric and IgA1 anti-human CEA and specific and neutralizing IgA1 and IgG1 are available for different influenza strains in order to set up vaccination protocols. HIV and bacterial mucosal infections. B Cell Design is also involved in other protocols as MANAGEMENT CEO immuno-allergist, Dr J Sainte-Laudy, CSO specialized in molecular biology, Armelle Cuvillier, Dr CTO specialized molecular biology applied to microbiology, Dr Gaël Champier, Design) (B Cell Abliance b-cell-design.com YEAR FOUNDED 2007 EMAIL [email protected] FAX +(33) 970 611 557 TELEPHONE +(33) 555 123 021 ADDRESS 87000 rue Legendre, 98, Limoges, France CONTACT Dr Jean Sainte-Laudy Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u OJSC AKRIKHIN www.akrikhin.ru FINANCIAL SUMMARY ≈150 mln EURO) ≈6 bln rubles ( Sales 2012: PROFILE COMPANY R&D original products) in several key therapeutic areas, generics, 150+ products (OTC, Part of Polpharma group, sales in Russia and CIS. Sales Force, semisolid and liquid forms, of solid, manufacturing capabilities, YEAR FOUNDED 1936 EMAIL + 7(495) 723 72 82 FAX + 7(495) 723 72 82 TELEPHONE +7 (495) 721 36 97 ADDRESS AKRIKHIN Moscow Office Business Center Towers Riverside Moscow, Russia, 115054, Kosmodamianskaya Naberezhnaya, 52 “AKRIKHIN” bld 5, CONTACT Business development department contact details [email protected] E-mail: +7 (495) 702-95-13 Tel.: WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Amakem N.V. Amakem www.amakem.com FINANCIAL SUMMARY €1.5M Seed round (Jan 2010) 2011) A round (Aug €18M Series PROFILE COMPANY Amakem’s Amakem is an ophthalmology company developing new treatments for serious eye conditions. Action platform which is designed to generate safe on its unique Localized Drug product pipeline is based and effective inhibitors that novel kinase with the aim of reducing side effects. minimize systemic exposure is for glaucoma and the Company is working to apply the Localized Drug AMA0076, lead candidate, Amakem’s AMA0076 is currently undergoing Phase 2a proof of concept Action approach to a range of other eye diseases. The Company has a second ophthalmology asset in preclinical development in an undisclosed indication. trials. development programsAmakem has preclinical in asthma/COPD and inflammatory Beyond ophthalmology, bowel disease. MANAGEMENT CEO PhD, Jack Elands, CSO Dirk Leysen, CMO MD, Steve Pakola, Preclinical Product Development PhD, Director, Olivier Defert, Head of CMC and Operations Maarten van Geffen, CBO PhD, Kieran Rooney,

YEAR FOUNDED 2010 EMAIL [email protected] FAX +32 (0) 11 490-209 TELEPHONE + 32 (0) 11 286-982 ADDRESS Amakem N.V. BioVille A bis Agoralaan bldg. 3590 Diepenbeek Belgium CONTACT PhD Kieran Rooney, Chief Business Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Anergis www.anergis.ch FINANCIAL SUMMARY from venture capitalCHF 22M funding received and private investors PROFILE COMPANY Anergis biopharmaceutical company SA is a Swiss-based specializing in the discovery and development of novel Anergis´its proprietary vaccines are based on Continuous allergy the most frequent allergies. vaccines targeting Allergies and the fastest growing are the most prevalent chronic Overlapping technology. Peptides (“COP”) with over 500 million people affected. world, conditions in the industrialized its AllerR, is in Phase II clinical development. a vaccine to treat birch pollen allergy, AllerT, Anergis’ lead-product vaccine candidate for the treatment of patients with allergy to ragweed pollen has received positive feedback Anergis’ vaccine candidate AllerDM, FDA for the final preclinical and early clinical program and from the U.S. Anergis has raised is progressing through preclinical development. for patients with house dust mite allergy, BioMedInvest and other investors Sunstone Capital, Capital, over CHF 22 million from Renaissance PME-Vinci and Defi Gestion. Ventures including Esperante COPs Anergisacid sequence of the allergen in separate COPs reproduce the full-length amino long peptides. COPs Therefore, the antibody class responsible for eliciting allergic hypersensitivity. do not cross-react with IgE, Studies can be safely administered at injections only. induce tolerance to the allergen after few high doses to in animals and in humans have confirmed the safety (no immediate allergic reaction) and of COPs in vitro, ANERGIS and cytokines immunogenicity (production of specific IgG4 antibodies the originalagainst allergen) of for a trend symptom improvement was observed during the season and AllerT, In a Phase I/IIA trial with COPs. long term follow-ups of the same patients demonstrated that antibodies against the birch pollen major allergen and two four seasons after bet v 1 were still significantly elevated with placebo-treated in comparison patients, AllerT. the very short one-time preseasonal treatment (5 SC injections in 2 months) with AllerT multicentre European trial is underway with randomized, placebo-controlled, A large double-blind, AllerT using recommended regulatory endpoints of combined symptom and to demonstrate the efficacy of of this trial are Results during the natural birch pollen season. i.e. medication scores in real-life conditions, AllerT for and/or to finance it through a Phase III Anergis intends to partner At this time, expected in Q3 2013. round B with current and new investors. MANAGEMENT CEO PhD, Vincent Charlon, CSO PhD, Christophe Reymond, Founder Allergy Expert, MD, François Spertini, MD, Clinical Development Gilles Della Corte, Product Development PhD, Eva Castagnetti, Affairs Regulatory PhD, Gerard Farmer, Business Development PhD, Jean Paul Rohmer, Finance MBA, Zoltan Czigler, YEAR FOUNDED 2001 EMAIL [email protected] FAX +41 21 651 9221 TELEPHONE +41 21 651 9220 ADDRESS BioPole III Route de la Corniche 9B CH-1066 Epalinges Switzerland CONTACTS Vincent Charlon PhD, CEO Zoltan Czigler MBA, Finance Director WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u GmbH Pharma Antisense www.antisense-pharma.com FINANCIAL SUMMARY Privately held company. fund. Equity lead investor is MIG BayernOthers are S-Refit and Kapital. PROFILE COMPANY developing innovative Germany, companyAntisense Pharma is a biotech based in Regensburg and Munich, The company’s TGF-ß pathway to treat with high unmet medical need. tumor diseases therapies targeting the has been granted orphan designation for three the anti¬sense oligonucleotide trabedersen, lead compound, been found has to be safe in several clinical trials and has shown encouraging Trabedersen tumor indications. The or malignant melanoma. pancreatic cancer, clinical activity in patients suffering grade from high glioma, and a key promoter of TGF-ß signaling complex, is a key component of the TGF-ß2, target of trabedersen, is believed to reverse by down-regulating its expression, Trabedersen, immuno¬suppression. cancer-derived resulting immune system and rendering the tumor visible to the patient’s the immuno¬suppressive effects, Antisense Pharma intends to immune response. anti-tumor in priming and specific activation of the patient’s the company is expanding its In addition, further validate this promising drug candidate in selected indications. oligo-nucleotide program identifying novel proprietary “Next Generation” pipeline through the development of a compounds to target cancer. MANAGEMENT Chief Executive Officer Philippe Calais, Dr. YEAR FOUNDED 1998 EMAIL [email protected] FAX +49-941-9201329 TELEPHONE +49-941-920130 ADDRESS 9 Josef-Engert-Str. 93053 Regensburg Germany Or: Leopoldstrasse 244 80807 Munich Germany CONTACTS Dr Philippe Calais CEO Andrea Kottke Dr Affairs & Head Medical Communication WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u APIM Therapeutics AS Therapeutics APIM www.apimtherapeutics.com FINANCIAL SUMMARY Capital Financed. Venture AS • Ro Invest • Norsk Innovasjonskapital Venture • Sarsia Seed • Birk Current investors include: PROFILE COMPANY AS is a Norwegian biotech company develop and commercialize novel anti-cancer set to Therapeutics APIM therapies potentiating chemotherapy-induced cells. responses in cancer protein called Proliferating cell “hub” offer a unique physiological interventionWe point targeting a cellular cell cycle control and apoptosis, repair, regulator PCNA acts a master of replication, Antigen (PCNA). Nuclear ultimately controlling responses to pathological (cancer) and pharmacological (chemotherapy) stress in cells. features a novel PCNA-interacting Stress Switch Peptide current preclinical lead, the company’s ATX-101, with several cellular defense interferes being incorporated in peptide sequence, This motif, APIM. Motif termed to chemotherapysystems dealing with stress resulting in both hypersensitivity and direct induction of apoptosis in selected cancer cells. including single has shown potent preclinical efficacy activity and potentiationagent of the ATX-101 Overall, vorinostat, dasatinib, decitabine, cytarabine, bleomycin, melphalan, action of >15 clinical drugs in vitro (cisplatin, and solid tumor indications. in animal models of blood cancer bortezomib and others) as well as proof-of-efficacy is being developed as a novel candidate drug for various oncology indications. ATX-101 Currently, MANAGEMENT Chief Executive Officer Alevizopoulos Ph.D., Kostas Chief Scientific Officer Marit Otterlei Ph.D., YEAR FOUNDED Founded in 2009 as a spin out from the Norwegian University in Technology of Science and Norway. (NTNU), Trondheim EMAIL [email protected] [email protected] TELEPHONE +41 78 752 7002 ADDRESS AS Therapeutics APIM AS Transfer Tech c/o NTNU Sem Sælandsvei 14 3etg Kjemiblokk 1, Trondheim N-7491 Norway CONTACT Alevizopoulos PhD Kostas Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Harald Fricke, M.D./Ph.D., CMO/COO M.D./Ph.D., Harald Fricke, he was responsible for at global clinical development Previously, Apogenix GmbH as CMO and COO in January 2006. He joined From 1996 to 2001 clinical development department. he was head of Baxter Oncology’s Prior to this, Fresenius Biotech GmbH. respectively. he held various national and international management positions at SmithKline Beecham and GlaxoSmithKline, Aachen and the University Lübeck. in 1987 after having studied medicine at the University of Fricke obtained his M.D. Dr. He joined Apogenix GmbH as CEO and CFO in November 2005. Prior to this, he worked as a stock analyst for DZ BANK, he worked as a stock analyst for DZ BANK, Prior to this, in November 2005. Apogenix GmbH as CEO and CFO He joined held various he From 1992 to 1996, AG. AG and Knoll he headed the CNS research at BASF From 1997 to 2000, Frankfurt. AG. research and management positions at BASF in 1991 for the doctoral work performed at Center (DKFZ) after the German Cancer Research obtained his Ph.D. Höger Dr. and as a Fulbright Scholar at the Massachusetts Institute of having studied biology atand Heidelberg, the Universities of Kiel USA). (Cambridge, Technology GmbH Apogenix www.apogenix.com FINANCIAL SUMMARY led by dievini rounds, 50m € raised in three financing 8.5m € public grants raised PROFILE COMPANY Apogenix is a clinical stage biopharmaceutical company protein therapeutics developing novel for cancer therapeutic candidates target either pathways inducing apoptosis or a pathway The company’s treatment. a CD95-Fc is Apocept™ (APG101), candidate, The lead product stimulatinggrowth tumor cell and migration. thereby in cancer cells inhibiting fusion protein that CD95 and its ligand CD95L, blocks the interaction between reached all clinical endpoints in Apocept has announced in 2012 thatApogenix their proliferation and migration. an actively study in patients controlled Phase II proof-of-concept with recurrent glioblastoma multiforme (GBM). Achieved secondary endpoints include The primary endpoint was progression free survival (PFS) at six months. with an excellent safety The outstanding efficacy was combined safety and tolerability. overall survival (OS), PFS, profile; no drug-related have serious adverse events been observed conducted so far with in all clinical studies It is the first compound in more than a decade to clearly deliver a PFS as well as an OS benefit in an Apocept. Apocept holds great other tumor indications promise in such byThe inhibition of CD95L actively controlled trial. a phase I Apocept´s potential in MDS, explore To as myelodysplastic syndromes (MDS) and pancreatic cancer. GBM are in preparation.Additonal studies in study in MDS patients has been initiated in January 2013. The company is based in Apogenix was founded Cancer Research Center (DKFZ). as a spin-out from the German and employs currently people. 27 Germany, Heidelberg, MANAGEMENT CEO/CFO Thomas Höger, Dr. YEAR FOUNDED 2005 EMAIL [email protected] FAX +49 6221 5860810 TELEPHONE +49 6221 586080 ADDRESS Im Neuenheimer Feld 584 69120 Heidelberg Germany CONTACT CEFA Thomas Höger, Dr CEO/CFO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Biomay AG Biomay www.biomay.com FINANCIAL SUMMARY exclusively provided by private investors. Biomay is privately held with a share capital of EUR 14.6 million, PROFILE COMPANY discovery and development of disease modifying allergy Biomay worldwide leader in research, aspires to be a will dramatically Our products of life of patients improve the quality by offering for long-term cure therapeutics. their disease. These allergy discover and develop recombinant a superior efficacy and safety profile. vaccines with We innovativescience for vaccines are based on cutting edge immunotherapy and prophylaxis that we generate in Our technology platformnovel peptide carrier fusion is based on a close cooperation with our academic partners. is the grass pollen allergy vaccine BM32, Our lead product, protein approach and is broadly patent protected. cat dander and we have candidate vaccines for house dust mite, In addition, currently in phase IIb clinical trials. birch pollen allergies in preclinical development. We cooperate with The clinical efficacy of our products is demonstratedmedical standards. under the highest leading allergy to revolutionize allergy specialists and industrial partners treatment solutions for the patients’ benefit. quality standards. products complies with the highest Manufacturing of our own and our clients’ development we support our clients by offering highly services. professional GMP contract manufacturing Additionally, MANAGEMENT CEO Rainer Henning, CFO Karl Fister, COO Hans Huber, Head of Product Development Angela Neubauer, YEAR FOUNDED 1984 EMAIL [email protected] FAX +43-1-7966-296-222 TELEPHONE +43-1-7966-296-100 ADDRESS Vienna Competence Center Lazarettgasse 19/1 Vienna A-1090 Austria CONTACT Rainer Henning CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Biotie Therapies Corp. Therapies Biotie www.biotie.com FINANCIAL SUMMARY Listed on NASDAQ Helsinki Ltd (BTHV1) OMX million ~EUR 200 Market cap: EUR 41.7 million Q3-2012: Cash position (liquid assets): PROFILE COMPANY development companyBiotie is a specialized drug focused on the development of drugs for neurodegenerative alcohol cognitive disorders, disease and other Alzheimer’s disease, Parkinson’s and psychiatric (e.g. disorders and inflammatory and fibrotic liver disease. and drug dependence (addiction) and post-traumatic stress disorder), The company portfolio has a strong and balanced development innovative with several small molecule and diseases with products address Biotie’s biological drug candidates at different stages of clinical development. potential. high unmet medical need and significant market has on 14 December A/S, licensed to Lundbeck SelincroTM (nalmefene), most advanced product, Biotie’s for2012 received a positive opinion from the Committee for Medicinal Products Human Use (CHMP) of the Agency (EMA) recommending marketing authorization of Selincro(TM) for the reduction of European Medicines In alcohol consumption in adult patients dependence who have with alcohol a high level of alcohol consumption. covering tozadenant which has successfully Biotie has a strategic collaboration with UCB Pharma S.A. addition, on Biotie shares are listed disease. completed a Phase 2b study in 420 patients advanced Parkinson’s with NASDAQ OMX Helsinki Ltd MANAGEMENT Management Team President and CEO Veromaa, Timo COO Ian Massey, 2013) CFO (effective February 25, David Cook, CMO Stephen Bandak, CBO Chris Piggott, Board of Directors: Chairman Peter Fellner, Ismail Kola and Guido Magni Kastler, Bernd Merja Karhapää, Burns, William M.

YEAR FOUNDED 2002; Listing date 31/10/2002 EMAIL [email protected] FAX +358-2-2748 910 TELEPHONE +358-2-274 8900 ADDRESS Therapies Corp. Biotie 6 Tykistökatu Turku FI-20520 Finland CONTACT Veromaa Timo Dr President & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Offer Nonhoff, CFO Offer Nonhoff, where he was a world market leader in the medical laser industry, from Lumenis, Offer Nonhoffcomes to BONESUPPORT Sales BeyondOffer finance was also responsible for Human Resources, the CFO for the EMEA region for the past 3 years. Administration and Order Processing. and for Siemens one of a start up company in the high tech media space, Animation Lab, Offer worked for Prior to Lumenis, the largest medical and electronic engineering companies in the world. In this role Offer Offerup through the ranks to become CFO rose for Siemens Israel. During his fifteen year career at Siemens, and in the enabled the company to achieve market leadership (with multi-million dollar revenues) in several fields of business, He lead the company to win the process became ranked in the top 500 in a company with in excess of 500,000 employees. and many bids for five power plants of which three are already in operation, first light rail system, Aviv’s Tel bid to implement advanced power transmission and medical imaging technologies. Offer switching arena was promoted to Financial Controller in the networking Accounts for Siemens in Germany, Beginning in establishing regional offices that represented the entire portfolio of the in Israel where he subsequently all investments, guided with Siemens Israel from start-up provided Offer the opportunity to Working Autonomy. company in Israel and the Palestinian IT and finance. controlling, accounting, perform in the areas of corporate leadership responsibilities management, Administration from the IHK in Munich. of Industrial Business receiving his BA Offer studied in Germany and the U.S., Mr. Diamond joined BONESUPPORT in January 2012 as the Chief Excecutive Officer. He is a seasoned medical device in January joined BONESUPPORT 2012 as the Chief Excecutive Officer. Diamond Mr. He held positions with leading global start up and matureexecutive with global experience and has worked in both companies. Kyphon and Conmed Linvatec (formerly Zimmer). Laserscope, companies such as Lumenis, but on the business side. became involved in his profession when he decided he wanted to work in health care, Diamond Mr. He now has 20 years of experience developing and development. He wanted to help improve health care through product Diamond has been involved in several successful Mr. In addition, launching disruptive technologies in the health care field. he helps companies to deliver better patient and health economic outcomes. Through his leadership, company turn arounds. therefore creating shareholder value. he makes companies provide new standards of care, Ultimately, holds a BS Degree Diamond in Biochemistry and Marketing as well as an MBA in International Finance from the Mr. 100 Top received the Red Herring Global under his leadership, BONESUPPORT, Thunderbird School of Global Management. in the world. citing them as one of the top entrepreneurial companies BONESUPPORT AB BONESUPPORT www.bonesupport.com FINANCIAL SUMMARY Most recently it raised EUR 19.2m / SEK 171m The company over €50M since inception. has raised (in July sales and market channels 2011) to expand and 44% by investors existing 56% of capital by was invested new investors, which is planned for Q4 2013 break-even, Funding will last past cash PROFILE COMPANY mission is to provide an injectable radiopaque bone substitute that been proven to has BONESUPPORT’s capable with the potential to be combined with other substances and is of being delivered remodel into bone, Its flagship product platform CERAMENT™ is an excellent treatment to be used as a option percutaneously. The latest It is clinically proven as it has been used in more than 4000 patients. synthetic bone substitute. filler which is indicated Void advance in the CERAMENT™ platform Gentamicin Eluting Bone is CERAMENT™G for use as an osteobiologic scaffold infectious environment. will protect the bone healing process in an and MANAGEMENT CEO Lloyd Diamond, YEAR FOUNDED 1999 EMAIL [email protected] [email protected] FAX +46 46 286 53 71 TELEPHONE +46 46 286 53 61 ADDRESS SCHELEVÄGEN 19A 223 70 Lund Sweden CONTACT Lloyd Diamond CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Bone Therapeutics SA Therapeutics Bone www.bonetherapeutics.com FINANCIAL SUMMARY EUR 30Mio Funds raised : PROFILE COMPANY Therapeutics a leading international is biopharmaceutical company focused on innovative cell therapy Bone knowledge of the bone/joint unique Utilizing the Company’s products for the treatment of bone diseases. Therapeutics has created Bone physiology expertise in cell therapy and long-standing and cell transplantation, tailored in- a fully integrated cell products, novel bone with an advanced product pipeline comprising business house production methods and minimally treatment invasive techniques. trials currentlyclinical III Phase in product, cell bone autologous an is PREOB®, Therapeutics’product, lead Bone Therapeutics is also developing an allogeneic Bone for the treatment fractures. of osteonecrosis and non-union a combined MXB, which is expected to enter the clinic in 2013 and ALLOB®, bone cell therapy product, All of Bone currently in preclinical development. cell-matrix product for the treatment bone defects, of large comply with all regulations Therapeutics’ cell therapy to the highest GMP standards, products are manufactured and are protected by a rich IP estate. with more in the world, of the largest healthcare markets The bone disease and reconstruction market is one Bone than 4 million procedures requiring bone grafts performed annually in Europe and the USA alone. Therapeutics is operating for in areas where demand new products is high and competition is low. MANAGEMENT CEO MBA, Enrico Bastianelli MD, CSO PhD, MD, Gangji Valérie YEAR FOUNDED 2006 EMAIL [email protected] FAX +32 (0) 2 529 59 93 TELEPHONE +32 (0) 2 529 59 90 ADDRESS Adrienne Bolland rue 8, 6041 Gosselies BELGIUM CONTACT MBA Enrico Bastianelli MD, Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u CellMed www.cellmed.at FINANCIAL SUMMARY CellMed is a non public mainly privately funded company national with certain support grants. PROFILE COMPANY a high potential dendritic cell based biotechnologyAustrian company PROCURE®, developing CELLMED is an indicationThe niche for this platform technology is ovarian cancer which is applicable forall solid vaccine. tumors in general. The company is led by an experienced management by team and supported a group of world renowned clinical experts in ovarian cancer. immunologicallyprove PROCURE® to be safe and Results from the phase I study in ovarian cancer active (proof The autologous dendritic cell therapy is manufactured in a of concept) with a positive trend in clinical efficacy. robust manufacturing process with the potential for automation. CELLMED plans to conduct a phase II study in cooperation best clinical cooperative with one of the groups in byovarian cancer and to achieve clinical proof of concept 2016. MANAGEMENT CEO MBA, MD, Huber, Wolfgang CSO PhD, Marianne Imhof, YEAR FOUNDED 2006 EMAIL [email protected] FAX +43 (0) 2732 70512-50 TELEPHONE +43 (0) 699 172 494 70 ADDRESS Magnesitstraße 1 Donau 3500 Krems a.d. Austria CONTACTS Huber Wolfgang Dr Chief Executive Officer Dr Marianne Imhof Chief Scientific Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u • fully native conformation, etc.), cleavage, homo- and hetero-oligomerization, • natural post-translational modifications(glycosylation, • accessory proteins. trigger specific immune response against receptor ectodomains, 1. select efficiently scFv phage library, 2. screen easily mAbs (ELISA), 3. characterize all mAbs-receptor interaction parameters (SPR). 4. Ciloa, SAS Ciloa, www.ciloa.fr FINANCIAL SUMMARY Private ownerships. PROFILE COMPANY Ciloa is an innovative company with a patented proprietary technology that provides fully native these recombinant exosomes Using called exosomes. on natural nanovesicles transmembrane proteins Ion Channels and Kinase Receptors, Ciloa develops mAbs against challenging targets such as GPCR, that carry both lipid membrane vesicles that Exosomes are small are secreted by many cell types, more. proteins and RNA and that possess potent immuno-stimulatory functions. Exosomes are tailored by Ciloa to express any type of membrane proteins (with single or multi-transmembrane with their: in a membrane, embedded at high concentrations, domains), the challenge to obtain fully native membrane proteins out of cells hampers dramatically the Currently, etc.). ion channels, development of therapeutic mAbs against membrane protein targets (receptors, important The disruptive technology open this lock by of Ciloa allows breaking producing not only the perfect membrane antigens but also byto: providing potent methods diagnostic, therapeutic, immuno-therapeutic, Ciloa exosomes can help also in drug screening, More, developments. and vaccine MANAGEMENT CEO/CSO Ph.D., Mamoun, Robert Z. CFO D., Ph. Coralie Philippe, Senior Scientist D., Ph. Renaud Burrer, D., Senior Scientist Ph. Manuela Lotierzo, Senior Scientist D., Ph. Maëlle Prorok-Hamon,

YEAR FOUNDED 2011 EMAIL [email protected] [email protected] FAX + 33 (0) 467 144 286 TELEPHONE + 33 (0) 467 143 997 CONTACTS Ph.D. Mamoun, Robert Z. ADDRESS SAS Ciloa, cc107 24, Bat. Universite Montpellier 2 Bataillon Place E. 34095 Montpellier cedex 5 France CEO/CSO Ph.D. Renaud Burrer, Senior Scientist WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u is a biopharmaceutical executive and positioned several companies to increase business value and competitive advantageis a biopharmaceutical executive and positioned several companies to increase business value and competitive Colby Pharmaceutical SAB CoChair & SILKI AG Chief Scientific Officer Colby Pharmaceutical SAB CoChair & SILKI Thomas Kündig MD, Company Pharmaceutical Colby AG & SILKI FINANCIAL SUMMARY Delaware is a C Corporation in good standing in USA-based Colby Pharmaceutical Company, San Jose California, DE and CA. PROFILE COLBY PHARMA COMPANY molecule and selling small marketing, Colby is an immunology and chemistry-driven drug company developing, vaccines treat novel drugs and disease and inflammatory Colby’s drugs or biologics modulating inflammation. The Company leverages capital asset out- from investors and infection and pain. cancer, especially, conditions, The Company is accessing reset and resell clinical stage assets. Colby continues to acquire, licenses and sales. Colby intends and in-licensed or reset assets. acquisitions, investments, grants, data generated from contracts, either independently or with a on advancing these drug candidates clinic to commercialization, through the partner. Immune Modulator Biologics US Based Division division of Colby was formed via a worldwide exclusive the immune modulator-biologics 2011, In September, of Juvaris BioTherapeuticsin-license acquisition of all the human health assets from KPCB (Kleiner Perkins immune Colby’s Abbott Bioventures (see 2011 press releases). and SV Life Sciences, Caulfield Byers), In modulator new Phase II hematology division is expecting to enter additional and oncology clinical trials. standalone immune activators for or adjuvants disease specific antigen vaccines can be addition Colby’s with assets from the including protocols being developed ILNI, Node Immunization, synergistic with Intra Lymph Zürich. AG, SILKI Colby Pharmaceutical subsidiary, Colby and collaborators have consistently recorded JVRS-mediated-dose-dependent human cancer patient some with anecdotal increases in human patient survival to be confirmed by follow-up therapeutic responses, The Company supply has a significant of JVRS-100 clinical grade material ready for initiation of Phase II trials. growth plans and facilitate its transition accelerate the company’s To multiple Phase II human clinical trials.. Colby management has secured significant to focus on Phase II efficacy data disease indications, in multiple and is recruiting additional professional staff and new collaborators. collaborators), partners, clinical assets, COLBY PHARMA EUROPEAN MANAGEMENT Colby Pharmaceutical COO Ken Narducy PhD MBA, Ken via R&D, IP generation and commercialization, M&A analysis, and venture funding. He developed new biotech/pharmaceutical and venture funding. M&A analysis, IP generation and commercialization, via R&D, Schering- Abbott Labs, products for Charles) and biomedical/chemical divisions of St. Centaur, business for startups (Oculex, including bringing colored contact Ken has completed over $1B in prior transactions,, The Cooper Companies. and Plough, lenses to market. YEAR FOUNDED 2004 Colby Pharma US EMail tkuendig @colbypharmaceuticals.com- knarducy @colbypharmaceuticals.com Colby Pharma US Fax Corp Fax (650)644-0440 Lab Fax (408) 960-3822 Colby Pharma US Telephone Co Phone (650) 323-6215 Cell Phone (650) 333-3150 Lab Phone (408) 960-7466 ADDRESS Colby European Colby Pharmaceuticals SAB Gloriastrasse 31, 8091 Zürich Switzerland Colby Pharma US Address 5941 Optical Court CA 95138 San Jose, CONTACTS Colby European Kündig MD Thomas M. ColbySAB, Pharmaceutical CoChair Mobile 078 609 35 36 Phone 04 255 34 71 Colby Pharma US Ken Narducy PhD MBA Colby Pharmaceutical COO Kündig MD Thomas M. Colby Pharmaceuticals SAB, Co-chair WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Covagen AG Covagen www.covagen.com FINANCIAL SUMMARY Ventech • • Edmond de Rothschild Investment Partners Fund Venture • Novartis Investors: Management Venture • MP Healthcare • Seroba Kernel Life Sciences PROFILE COMPANY develops bispecific FynomAbs™ proteins to antibodies by fusing its human Fynomer™ binding Covagen resulting in therapeutics treatment in the with novel modes-of-action and enhanced efficacy of inflammatory The abilityallows Covagen sites on an antibody to fuse Fynomers™ to multiple to create diseases and cancer. efficacy. FynomAbs™ with tailored architecture to maximize TNF/IL-17 inhibitor (in preclinical development) for the treatment of lead program is a bispecific Covagen’s psoriatic arthritis and rheumatoid arthritis. inflammatory diseases such as psoriasis, MANAGEMENT of Directors Board Chairman Franz Hefti, Julian Bertschinger Jon Hepple, Mounia Chaoui, Gilles Nobécourt, Anja König, Ray Hill, Advisory Board Scientific Christoph Lengauer Christoph Heusser, Thierry Hercend, Ulrich Feige, Winter, Greg YEAR FOUNDED 2007 EMAIL [email protected] FAX +41 44 732 46 64 TELEPHONE +41 44 732 46 60 ADDRESS AG Covagen 25 Wagistrasse 8952 Schlieren, Switzerland CONTACTS Dr Julian Bertschinger Chief Executive Officer Dr Dragan Grabulovski Chief Scientific Officer Dr Fabian Buller Director Business Development WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Generation of highly and safety data promising in vivo efficacy CriPec® docetaxel when compared with Taxotere with • Development of sophisticated process of CriPec® nanoparticles GMP-manufacturing •  increasing the in vivo half-life time 50-fold. • Expansion of CriPec® approach to peptides: B.V. Delivery Cristal www.cristaldelivery.com FINANCIAL SUMMARY Ventures and BioGeneration VC firms, Cristal Delivery Dutch has closed in 2012 a financing round with two The company is presently funds that in the process of raising additional will enable the finalisation of Thuja. clinical phase I/IIa. PROFILE COMPANY Cristal Delivery is a pharmaceutical company that first-in-class nanomedicinal products on the develops CriPec® enableswith a the development products base of its proprietary polymeric technologies (CriPec®). The clear competitive edge as a result of their anticipatedand improved tolerability superior efficacy profile. accumulation preferential of customisable platform allows for disposition of the entrapped an improved drug, the possibility to be combined with ligands for active targeting and is CriPec® in tumour and inflammatory sites, easily manufactured. CriPec® is a unique approach to transform into nanomedicines of around 70 nm and which possess drugs as already demonstrated efficacy and safety profile multiple beneficial properties resulting in an improved in which comprises Both small molecules and peptides can be combined with CriPec® various preclinical studies. products that take the (physico)chemical properties it allows for tailor-made all key factors for a successful drug: the desired concentration at the target site and the route of administration account. into of the drug, ‘s enabling technology opportunities in with new or existing drugs will expand The combination of CriPec® that will also open up new areas in diseases The resulting products have been so various therapeutic areas. The company strategy is to leverage its technologies by building a small product portfolio for far hard to treat. Cristal Delivery Next, scheduled with CriPec® docetaxel earlyA first clinical trial is 2014. various indications. is actively pursuing strategicwith pharmaceutical companies to conduct custom-made feasibility partnerships studies to create innovative competitive advantages. products with compelling 2012 was a reallyprogress exciting year as noteworthy has been made in the development of CriPec® as well Last year milestones were: as the first product. MANAGEMENT CEO Dr Cristianne Rijcken, Executive Director Dr Joost Holthuis, YEAR FOUNDED 2011 EMAIL Cristianne.rijcken @cristaldelivery.com Joost.holthuis @cristaldelivery.com TELEPHONE +31 30 430 0222 ADDRESS Padualaan 8 3584 CH Utrecht The Netherlands CONTACT Dr Cristianne Rijcken Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Cureline, Inc. Cureline, www.cureline.com FINANCIAL SUMMARY Privately owned company. PROFILE COMPANY diagnosticsCureline is a biomarker and and acquisition human biospecimens CRO specializing since 2003 in specimen clinical network management, regulatory affairs, including study design, tissue research projects inflammation, immunology, are oncology, Our areas of expertise and complete logistics. collection and analysis, collaborate with major clinical We infectious diseases/sepsis/HIV. metabolic conditions, cardiovascular conditions, and the USA and maintain an extensive biorepository of human biospecimens in South Asia, centers in Europe, Cureline BioPathology (translational histology CLIA/GLP laboratory)San Francisco (USA). provides high-end and clinical specimens processing and diagnostics, tissue research services including IHC protocol development, patient Petersburg (Russia) supports regulatory affairs, European clinical outreach group in St. digital pathology. All our managers research. and marketing site relation clinical management, enrollment and retention services, research and healthcare management have advanced degrees in clinical trial operations, and are experienced and international business development.. MANAGEMENT CEO and Scientific Director PhD, Olga Potapova, SVP Biospecimen Operations MD, Alexander Lituev, SVP Finance and Operations Talmadge, Kathleen VP Business Development MBA, Irina Zaytseva, YEAR FOUNDED 2003 EMAIL [email protected] FAX +1-650-875-6484 TELEPHONE +1-650-875-6400 x 221 ADDRESS Ste 300, Ave 290 Utah South San Francisco, CA 94080 USA CONTACT PhD Olga Potapova, CEO and Scientific Director WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u www.domaintherapeutics.com Therapeutics Domain FINANCIAL SUMMARY 2008 – 2.1m€ 2012 – 2.0m€ PROFILE COMPANY dedicated to the discovery France, Therapeutics is a biopharmaceutical company located Strasbourg, in Domain of the best one and early (GPCRs), Receptors of small molecules targeting G-coupled Protein development Therapeutics is using its innovative and proprietary technology platform Domain to classes of drug targets. Allosteric Modulators (SAMs) that represent a unique including Silent identify orthosteric and allosteric ligands, The platform is also able to address source of compounds that by cannot be discovered standard technologies. pipeline is composed of new chemical The company’s difficult GPCRs such as orphans and peptidic receptors. entities ranging hot GPCRs for from hits to optimized leads targeting indications leading such as schizophrenia, disease and diabetes.. Parkinson’s MANAGEMENT CSO CEO, Pascal Neuville, Gregory Chapron, CFO Head of Research Stephan Schann, YEAR FOUNDED 2008 (restart) EMAIL contact @domaintherapeutics.com amaisner @domaintherapeutics.com msidhoum @domaintherapeutics.com FAX +33 39 040 6155 TELEPHONE +33 39 040 6150 ADDRESS BioParc 850 Bld Sebastien Brand 67400 Illkirch France CONTACTS Aurelie Maisner Mrs Assistant CEO Dr Marjorie Sidhoum Business Manager WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG Biotech Dualsystems www.dualsystems.com PROFILE COMPANY Contract Research OrganizationDualsystems Biotech is a drug and target profiling and in the areas of provide innovative complexes and small molecule – and flexible solutions to characterize protein We proteomics. target interactions in any cellular setting. for of action we identify and characterize novel mechanisms drugs using cell based with our partners, Together screening assays. provider of custom screening servicesDualsystems Biotech is a specializing in for industry and academia, AP/MS-MS and cDNA Library Construction. CaptiVate two-Hybrid, Yeast including protein Dualsystems provides kits and reagents for a range of research applications, In addition, protein-protein interaction and protein activity measurement expression, MANAGEMENT Finance Business Development, CEO, Schulze, Andreas J. Dr Operations CEO, Auerbach, Dr Daniel Director Services Mrs Katrin Rutschmann, YEAR FOUNDED 2000 EMAIL [email protected] FAX +41 44 738 55 05 TELEPHONE +41 44 738 50 01 ADDRESS Grabenstrasse 11a 8952 Schlieren CONTACT Schulze Andreas J. Dr CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ennar Pharma AG Pharma Ennar www.ennarpharma.com FINANCIAL SUMMARY a Basel based venture capital company and by The company is financially supported by an investment by EVA- the private founder. funds of the PROFILE COMPANY Ennar Pharma was founded in July topical treatment 2010 to develop a better and safer for mild-to-moderate The company is have been granted in Europe and the USA. protecting the technology, Patents, psoriasis. capital a Basel based venture company- the and has developed financially supported by an investment by EVA- The cGMP production of high-quality production of pure EGF and a stable pharmaceutical product. cream-based The IMPD for the topical product is EGF (epidermal growth factor) is carried out by a third-party collaborator. Swissmedic-approved trial is running at and the Proof-of-Concept Dermatology the Clinic of the University of aims to establish the validity which is carried out with mild-to-moderate psoriasis patients, The trial, Zurich. of the mode-of-action proposed for topical formulation the EGF-based and test the optimised formulation for Results of the trial are expected by the end of Q1 2013. clinical efficacy and safety. MANAGEMENT Chief Executive Officer Dr Rudi D Neirinckx, Board Member Dr Peter Burckhardt, YEAR FOUNDED 2010 EMAIL [email protected] TELEPHONE 061 283 8485 ADDRESS Hochbergerstrasse 60c CH-4057 Basel Switzerland CONTACTS Dr Rudi D Neirinckx Chief Executive Officer Dr Peter Burckhardt Board Member WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u AG Epigenomics www.epigenomics.com FINANCIAL SUMMARY ISIN DE000A1K0516). (ECX, Standard: Prime Epigenomics is publicly listed at the Frankfurt Stock Exchange, website. For financial information please refer to the Investor Relations of the Company’s section PROFILE COMPANY diagnosticsEpigenomics is a molecular company a pipeline of proprietary developing and commercializing products enable diagnose doctors to cancer earlier and more accurately, The Company’s products for cancer. is a blood-based test Epi proColon®, Epigenomics’ lead product, forleading to improved outcomes patients. which is currently is in development for marketed in Europe and the for the early detection of colorectal cancer, technology have and products been validated through multiple partnerships with leading The Company’s U.S.A. Epigenomics is an and Quest Diagnostics. Sysmex, QIAGEN, Abbott, global diagnostic companies including international company with operations and the U.S.A. in Europe MANAGEMENT Epigenomics is lead by a highly skilled and motivated management team with track records in the industry in the and Europe. U.S. Burrill & Company). Venture, Deutsche Therapies, (formerly Biotie Taapken Thomas The team is headed by Dr. CEO/CFO Taapken, Thomas Dr YEAR FOUNDED 1998 EMAIL [email protected] FAX +49 30 24 34 5 - 555 TELEPHONE +49 30 24 34 5 - 0 ADDRESS AG Epigenomics 1 Kleine Präsidentenstr. 10178 Berlin Germany CONTACT Antje Zeise Manager IR | PR WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u S.A. ERA BIOTECH www.erabiotech.com FINANCIAL SUMMARY Privately held. PROFILE COMPANY innovations developing break-through for existing biotechnologyERA BIOTECH® is a mid-size company, forenzymes and step-changes novel recombinant protein and DNA vaccines. international commercial organization call ourselves a science-based and are with 20 highly educated, We based in Barcelona at Park the Science scientists and product developers, visit at http://www.erabiotech.com Please, MANAGEMENT CEO Mr Lieven De Smedt, CBO Dr Miriam Bastida, IP Manager Dr Pau Marzábal, YEAR FOUNDED 2002 EMAIL [email protected] [email protected] [email protected] FAX +34 93 403 47 72 TELEPHONE +34 93 403 47 73 Office: ADDRESS Parc Científic de Barcelona 15-21 - 08028 C.Baldiri i Reixac, Spain Barcelona, CONTACTS Dr Miriam Bastida CBO Mr Dídac Marco Business Developer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Scientific Career: Max-Delbrück-Centre for Molecular Medicine (Berlin), MRC Centre for Protein Engineering (Cambridge, UK), UK), MRC Centre Engineeringfor Protein (Cambridge, Max-Delbrück-Centre for Molecular Medicine (Berlin), Scientific Career: German Cancer Research Centre (Heidelberg) • AplaGen GmbH, Co-Founder & former Co-Founder CEO/CFO AplaGen GmbH, • • Co-Founder and Investor in other small Biotechs Head of Pharma & Life Sciences • Kienbaum Management Consultants Principal, Consultant • Ernst &Young, • CEO/Co-Founder of Nemod GmbH (merged to Glycotope) in Biochemistry • Ph.D. •  Dr Franzpeter Bracht, CFO/CBO Glycotope www.glycotope.com FINANCIAL SUMMARY 125m. investment € Total PROFILE COMPANY biotech company GmbH is a German founded technologies in 2001 with new and 4 phase I/II GLYCOTOPE the company at has more than 150 employees total two sites in Berlin and Heidelberg and a Today products. out of a technology First product comes against developing new antibodies glyco-targets investment of €125m. we own a novel and regulatory approved cell lines system based on human GlycoExpress, With (GlycoBodies). prolonged half higher activity, leading to an optimized glycosylation, if desired, that confers a fully human and, develops NBEs and second generation GLYCOTOPE Using this technology, life time and reduced immunogenicity. a monoclonal antibody (GlycoBody) 2.5-GEX, such as GT-MAB antibodies and other non-antibody proteins, leading to that recognizes a combination backbone as well as the attached of its target protein glycosylation, PankoMab is scheduled to proceed to extremely with a high binding affinity. specific target recognition combined phase II in ovarial cancer in Q2/2013. two second generation antibodies are exhibiting superior features as compared to their originals: In addition, will enter Trastuzumab an improved TrasGEX, a 2nd generation Cetuximab and CetuGEX, the 2 most advanced, III in Q1 2014. FSH-GEX finished Phase II in Q3/2013 and will start Phase phase II in Q3/2013. MANAGEMENT Founder Dr Steffen Goletz, CEO/CSO, YEAR FOUNDED 2001 EMAIL [email protected] FAX + 49 30 9489 2630 TELEPHONE + 49 30 9489 2600 ADDRESS Glycotope GmbH 10 Robert-Roessle-Str. 13125 Berlin Germany CONTACTS Steffen Goletz CEO/CSO Franzpeter Bracht CFO/CBO Marcel Kuehnert Operations WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u GRL Inc. www.grl-inc.com FINANCIAL SUMMARY GRL is privately held. PROFILE COMPANY diagnosis and therapeutic treatment of and built companies focused acquired in detection, GRL has founded, The company has partnership relationships with CustomArray Inc (Semiconductor based microarray disease. founded platform for rapid disease/biothreat detection and identification – privatized from Combimatrix), A and B through AnaViRx Inc (orally available antiviral that has shown excellent efficacy against Influenza (siRNA therapeuticnovel mechanism) and was an angel investor in Sirnaomics development using proprietary nanoparticle delivery systems). AnaViRx (founded rights for in 2013) has inlicensed worldwide of a novel orally development available has a good safety profile and This small molecule is easily manufactured, A and B. therapeutic against Influenza A or type B infection has demonstrated for a 50% reduction in the time symptoms in flu in patients with type The compound has shown efficacy against a wide array of flu with a reduction in viral load in these patients. partners and/or funding to drive clinical development are seeking We H3N2 and H5N1). strains (including H1N1, of these molecules through USFDA and EMEA.

YEAR FOUNDED 2006 EMAIL [email protected] [email protected] FAX +301-740-1731 TELEPHONE +301-740-1730 ADDRESS Suite 130 401 Professional Dr., MD 20879 Gaithersburg, USA CONTACTS Mike Ghias CEO David Evans CSO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Total = 455 Total Switzerland = 277 Ireland = 141 USA = 37 Helsinn Healthcare SA Healthcare Helsinn www.helsinn.com FINANCIAL SUMMARY 243.9M CHF 300.2M – EUR Turnover: Net Total 2011 Helsinn Group’s CHF 436.1M – EUR 359.2M Assets: Total 2011 Helsinn Group’s CHF 298.5M in last 5 years: R&D Investments Helsinn Group’s Staff: Helsinn Group’s PROFILE COMPANY and operating Switzerland, Helsinn is a privatelygroup owned pharmaceutical with headquarters in Lugano, business model is focused on the licensing of Helsinn’s subsidiaries in Ireland and the United States. Helsinn Group medical devices and nutritional supplement products in therapeutic niche areas. pharmaceuticals, the performance completes their development through in-licenses early-to-late stage entities, new chemical and files and and Control (CMC) development, Manufacturing, of pre-clinical /clinical studies and Chemistry, marketing products are out-licensed to its network of local Helsinn’s attains their market approvals worldwide. selected for Helsinn assists their deep in-market knowledge and know-how whom and commercial partners, including commercial, and supports by and scientific management providing a full range of product services, ingredients The active pharmaceutical and the finished and medical marketing advice. legal, regulatory financial, and environmental standards at Helsinn’s safety, quality, products are manufactured according to the highest worldwide to its customers. GMP facilities in Switzerland and Ireland and supplied Further information on Helsinn Group is available at www.helsinn.com. MANAGEMENT Founder & Chairman Dr Gabriele Braglia, Board Member & US Chairman Helsinn Group CEO, Dr Riccardo Braglia, Board Member & US Board Member Group Chief Financial Officer, Dr Luigi Caletti, Group General Manager & Chief Operating & US Board Member Officer Dr Giorgio Calderari, Head of Corporate Business Development Senior Director, Dr Roberto De Ponti, Chief Commercial Officer Andrea Meoli, Dr Chief Scientific Officer Dr Sergio Cantoreggi, Affairs Corporate Legal General Counsel, Senior Director, Dr Matteo Missaglia, Technical Head of Corporate Senior Director, Dr Daniele Bonadeo, Advanced Synthesis Helsinn Chemical Business, Local General Manager, Dr Paolo Guainazzi, Ireland Helsinn Birex Pharmaceuticals, Pharma Business, Dr Padraig Somers, Local General Manager, Inc. Therapeutics (U.S.), Helsinn Local President & CEO & Board Member US Pharma Business, William Mann, Dr YEAR FOUNDED 1976 EMAIL [email protected] [email protected] FAX +41 91 993 21 22 TELEPHONE +41 91 985 21 21 Roberto De Ponti +41 91 985 21 21 Direct line: ADDRESS Helsinn Healthcare SA Via Pian Scairolo, 6912 Lugano-Pazzallo Switzerland CONTACT Roberto De Ponti Head of Corporate Business Development WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u • Physicist, Physics department MSU • Physicist, COO Andrey Kondratovich, Physics department MSU • Physicist, CTO Ataullakhanov, Fazly Prof. PhD, Sc., • Dr. • Moscow State University • Head of blood biochemical laboratory HSC RAS CSO Michail Panteleev, Prof PhD, • Dr.Sc., • Moscow State University • Chief of laboratory of molecular mechanisms in CTP PCP RAS CMO Ilya Serebriysky, hematologist • MD, HemaCore LLC HemaCore www.hemacore.com FINANCIAL SUMMARY Currently company Sberbank Capital. A financing in 2010 from Rusnano and Company round raised $19M HemaCore looks for round B in Russia. started serial manufacturing and started sales finished the development, in 2013 for trials in Europe and CE-IVD certification. GCP clinical PROFILE COMPANY main The for developing medical devices and methods hematology. company, HemaCore LLC is a biotech which – a new global assayThrombodynamics for monitoring and anticoagulant blood clotting control, product is Thrombodynamics analyser and disposables sales in Russia started in is highly sensitive to hypercoagulation. November 2012. MANAGEMENT CEO Igor Pivovarov, YEAR FOUNDED April 2010 EMAIL [email protected] FAX +7 499 152 37 54 TELEPHONE + 7 495 258 25 38 ADDRESS 4th 8 Marta street, 3, Moscow 125319, Russia CONTACT Anna Dushina WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ltd Therapeutics Heptares www.heptares.com FINANCIAL SUMMARY Venture Fund and Novartis MVM Life Science Partners, Ventures, date$40M venture finance to from Clarus Ventures. Takeda PROFILE COMPANY a superfamily of Heptares createsmedicines targeting previously new undruggable or challenging GPCRs, design approach are pioneering a structure-based drug to GPCRs, We receptors linked to many diseases. and fragment-based leveraging structure determination, proprietary technologies for protein stabilisation, Our objective is to build a broad Takeda. MedImmune and AstraZeneca, Our partners include Shire, discovery. disease, Alzheimer’s including pipeline of novel medicines to transform the treatment of serious diseases, migraine diabetes. and addiction, chronic insomnia, depression, schizophrenia, disease, Parkinson’s disease Alzheimer’s Our in-house pipeline is led by M1 programme our selective muscarinic for cognition in Our adenosine which is in preclinical development and slated for Phase 1 studies in 2013. and Schizophrenia, Further discovery is also in development for neurological disorders. licensed to Shire, A2a antagonist candidate, driven by our proprietary first-ever Family B crystalT2DM, programmes include oral GLP-1 agonists for and CGRP antagonists for prophylaxis and treatment of migraine. structure, opening up new The Heptares technology platform a unique GPCR capability represents in the industry today, Heptares possibilities for therapeutics both small molecule and antibody across the GPCR target universe. which are typically highly unstable when removed from is the first and only company transforming GPCRs, StaRs® enable GPCR structures in their natural into stabilised receptors or StaRs®. cellular membranes, thereby barrier to structure- overcoming a major historical pharmacological conformations to be determined, provides superior which invented Biophysical Mapping™, Heptares has also based GPCR drug discovery. and has engineered new fragment-based silico technologies and in elucidation of GPCR-ligand interactions, coupled with These technology breakthroughs, specifically tailored to GPCR lead discovery and optimisation. form the nucleus of a powerful and fully-integrated drug deep expertise in GPCR chemistry and biology, discovery platform. please visit www.heptares.com learn more about and technology the Heptares pipeline platform, To MANAGEMENT Co-Founder and CEO Weir, Dr Malcolm Co-Founder and CSO Dr Fiona Marshall, CBO Dr Barry Kenny, President Dan Grau, VP Chemistry Dr Miles Congreve, CMO and Head of Development Dr David McGibney, YEAR FOUNDED 2007 EMAIL [email protected] FAX +44 (0)1707 35840 TELEPHONE +44 (0)1707 358 629 (dl) +44 (0)7968947268 (m) ADDRESS Therapeutics Ltd Heptares BioPark Broadwater Road Garden City Welwyn AL7 3AX Hertfordshire CONTACT Weir Malcolm Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u biotechnologies immatics www.immatics.com FINANCIAL SUMMARY raising a total of €108m. immatics successfully concluded a total of three financing rounds, VCs. comprised of family offices and The company by is backed a particularly strong investor group, PROFILE COMPANY immatics of cancer immunotherapy. active in the field immatics is a clinical stage biopharmaceutical company, Associated Peptides) therapeutic vaccines that are active against cancers (=Tumor TUMAP-based is developing of which were developed with its proprietary all Three product candidates, need. with a high unmet medical from its products Phase II results technology platform XPRESIDENT™ are currently in clinical development. IMA901 in RCC and IMA910 in CRC showed a correlation of the number of peptides that patients responded to is presently in RCC, IMA901 The furthest advanced product, and the clinical benefit these patients experienced. All of immatics’ off current products are the shelf products. which is fully recruited. in a clinical Phase III trial, to find out more about immatics. Please visit our website at www.immatics.com MANAGEMENT CEO Paul Higham, CSO Harpreet Singh, CMO Carsten Reinhardt, CBO Rainer Kramer, YEAR FOUNDED 2000 EMAIL [email protected] FAX +49 7071 5397-900 TELEPHONE +49 7071 5397-0 ADDRESS immatics biotechnologies GmbH Paul-Ehrlich-Straße 15 Tuebingen 72076 Germany CONTACTS Mark Bleckmann Director & Head of Finance Wiegeler Nikola Communications WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Pharmaceuticals Immune www.immunepharma.com COMPANY PROFILE COMPANY is a global clinical stageIMMUNE Pharmaceuticals bio-pharmaceutical company the merger of resulting from and EpiCept Corporation(NASDAQ (“EpiCept”) OMX Stockholm Exchange and a privately company, held Israeli combined companyThe is focused antibody therapeutics on developing drugs and other targeted EPCT). OTCQX: is BERTILIMUMAB, lead product candidate, IMMUNE’s for the treatmentinflammatory of diseases and cancer. a chemokine involved in eosinophilic a first in class fully monoclonal antibody that human targets eotaxin-1, double-blind Phase Immune has initiated a placebo-controlled, angiogenesis and neurogenesis. inflammation, II clinical trial with bertilimumab for the treatment of ulcerative and plans to initiate colitis in 2013 additional Verneal a dermatological orphan condition and in in bullous phemphigoid, clinical studies in severe asthma, The companies’ collective oncology portfolios comprise: an ocular orphan condition. Kerato-conjunctivitis, vascular disruptive agents. and EpiCept’s a new generation of antibody drug conjugates, NanomAbs®, Immune’s Phase III clinical Immune Pharmaceuticals will continue efforts to secure a development partner for EpiCept’s designation for the treatment of Track for the FDA has granted which Fast AmiKet™, development candidate chemotherapy-induced neuropathic pain Status IMMUNE pipeline includes: II VKC – Phase Bullous Pemphigoid, Asthma, Severe • Bertilimumab Ulcerative Colitis, • Ferritin targeted combo Gem-Pac NanomAbs EPICEPT pipeline includes: AMIKET Chemotherapy Induced Peripheral Neuropathy – Phase III • – Phase II Tumors Azixa – Brain • – Phase II Tumors • Crolibulin – Solid TECHNOLOGY a novel alternative to NanomAbs are conjugates and monoclonal antibodies, of drug loaded nano-particles This technology They delivery allow targeted of anti-cancer agents to tumor cells. Antibody Drug Conjugates. was developed by Professor Benita at University of Jerusalem and has been licensed by Hebrew IMMUNE from IMMUNE is also making the technology IMMUNE is advancing its own candidates toward the clinic. YISSUM. available as part of co-development agreements. MANAGEMENT Chairman and CEO Teper, Dr Daniel Vice Chairman of the Board Dr David Sidransky, CFO will become the combined company’s Robert Cook, Chief Business Development Officer Suzy Jones, Board Member Dr Isaac Kobrin, Allard,CMO Dr Stephane SVP & COO Serge Goldner, Director of Research Dr Oshrat Frenkel, YEAR FOUNDED 2010 EMAIL [email protected] [email protected] TELEPHONE +972-9 8866612 Israel: USA: +646-588-5430 ADDRESS Israel: Herzliya Aba Even 15, USA: Americas, of the Avenue 1120 14th Floor NY 10036 York, New CONTACTS Teper Daniel Anna Baran WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Immunovaccine Inc. Immunovaccine www.imvaccine.com FINANCIAL SUMMARY 63.5M Shares outstanding: $23.5M Recent Market Cap: $0.37 Recent share price: $0.20 – $0.45 Range: Week 52 32,000 Volume: Daily Average $3.6M (30/09/12): Cash & Other Cash Resources PROFILE COMPANY Immunovaccine is a biotechnology company focused on the application of its novel vaccine delivery platform to platform DepoVax™ The Company’s the development of vaccines for cancer therapy and infectious diseases. is a patented lipid delivery system that system for presents antigens plus adjuvant to the immune a prolonged Immunovaccine has advanced its platform responses. period and has the potential to enhance immune trials were successfullyThese technology and proprietary cancer vaccines through Phase I clinical trials. completed demonstrating vaccine programs. potential in two cancer both safety and immunogenicity Immunovaccine is also capitalizing potential of its delivery on the broad platform by creating new DepoVax-based and government partners. academic, vaccines through multiple development collaborations with corporate, it continues to capture health value from animal human health vaccine strategy, In addition to the Company’s Immunovaccine has several key including an partnerships in the animal health sector vaccine applications. delivery technology platform to develop which has licensed the Company’s Animal Health, agreement with Pfizer vaccines for livestock. MANAGEMENT CEO Trizzino, John J. Business Development VP, Vicki Morgan, CFO Kimberly Stephens, CSO Ph.D., Marc Mansour, of Directors Board Pulitzer Prize Recipient Communications Strategist, Albert Scardino, Chairman, 2010 Inductee Canadian Medical Hall of Fame MD, William Cochrane, CEO of Brigus Gold Dawe, Wade of Investments GrowthWorks Sr.VP CA, James Hall, Partners Torreya Advisor to Senior Stephanie Léouzon, Former President and CEO of Sanofi Pasteur Pisano, Wayne CEO of Oncolytics Thompson, Brad YEAR FOUNDED 2000 EMAIL [email protected] [email protected] FAX 902-492-0888 TELEPHONE 902-492-1819 ADDRESS Suite 412 1344 Summer Street, Nova Scotia Halifax, B3H 0A8 CANADA CONTACTS Trizzino John J. Chief Executive Officer Vicki Morgan Business Development VP, WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Implandata Ophthalmic Products GmbH Products Ophthalmic Implandata www.implandata.com FINANCIAL SUMMARY A round. series €3.7m raised in seed and Currently the company is going to raise a €5m serious B round for market launch in Europe and US regulatory approval. profitability in 2016. in 2014, First revenues are expected PROFILE COMPANY products for developing ophthalmic monitoring and improved Implandata device start-up company, is a medical management of glaucoma patients. By continuous monitoring of goal of anyReduction of intraocular pressure (IOP) is the main therapy. glaucoma therapy and compliance of glaucoma patients can be dramatically improved. IOP, information office visits will reveal vital IOP 24h IOP measurements and measurement between on the therapy Remote patient management more efficient patient allows of therapy. “titration” outcome and ensure early on care. which is continuously telemetrically and monitoring The company has developed an implantablemicro sensor, This data is sent to the eye The measured data device for is sent to an external data display and storage. the IOP. office via tele-medical integration. doctor’s The company is currently studies for conducting clinical attaining CE mark for its first product in 2013. Regulatory approval Thereafter the companyfor the US market is expected will perform in Europe. a first launch followed by the market launch. in 2015, The companyIP position and collaborationpipeline and can trust on a sound has further products in the R&D with prestigious and scientists. sites and world class clinicians MANAGEMENT CEO Ostermeier, Max G. CTO Stefan Meyer, Head of SAB (UCSD), Weinreb Robert N. Prof. YEAR FOUNDED 2010 EMAIL [email protected] [email protected] FAX +49 511 2204 2589 TELEPHONE +49 511 2204 2581 ADDRESS Kokenstrasse 5 0159 Hannover Germany CONTACT Ostermeier Max G. CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Insuline-Medical Ltd Insuline-Medical www.insuline-medical.com PROFILE COMPANY – INSL) focused improving the performance on of current a Public Israeli company is (TASE Insuline Medical Ltd. Even with by trying to better approximateinsulin treatment for methods human physiology. diabetic subjects, Our to normal physiology. injected insulin kinetics is still slow compared rapid acting insulin analogs, today’s in order to improve and stabilize solutions are disposable devices which treat with heatinjection, the point of or as a standalone disposable be integrated It can into catheters pumps, used with insulin blood perfusion. compatible or pen delivery. with syringe while seemingly straight forward perfusion effectiveness requires balancing blood while also The technology, It is protected by patents pending globally, avoiding overheating the insulin itself above the allowed threshold. and involves significant device knowhow. have recently We have recently submitted our FDA application forWe the infusion pump device (InsuPatch). with device forpublished Interim results from large study conducted injections (InsuPad) in Germany. insulin The primary was end point forThis study was planned with the BARMER sick fund purposes of reimbursement. interim analysisThe showed reduction of device is used. reduction in prandial Insulin dose when the InsuPad about and control groups. 30% in prandial insulin dose between test to have CE mark for our products and we are building independent go-to-market ability in Germany first, We In preparation for launching the injection product in Germany we to Europe and the US. be expanded later on, and are gearing up towards manufacturing and have formed a fully owned subsidiary (InsuLine-Medical GmbH), pre-marketing studies. MANAGEMENT President & CEO Ron Nager, David Ben-Naim, CFO VP R&D Gabriel Bitton, VP Operations Noam Kfir, YEAR FOUNDED 2007 EMAIL [email protected] FAX +972-3-9341094 TELEPHONE +972-3-9301094 ADDRESS 70 Pinsker Street 10299 P.O.Box Tikva Petach Israel 4900202 CONTACT Mr Ron Nagar President & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u i-Optics www.i-optics.com FINANCIAL SUMMARY Not disclosed. PROFILE COMPANY designed to Our products are in smart and superior eyei-Optics is a leading pioneer diagnosis solutions. and easy to use by fast the world to better serve care providers all over patients in the most be affordable, Germany and and USA through our direct sales force sell our products in Netherlands, We convenient way. Our product portfolio includes: have key distributors in other markets. A fast and easy to use retinal imaging system based on SLO technology for cleared). FDA EasyScan (CE, age-related macular degeneration and glaucoma. the diagnosis of diabetic retinopathy, A first of its kind corneal topographer based on the principle of color LED cleared). FDA Cassini (CE, that and cateract supports premium contact lens fitting and planning of refractive surgery topography (CLT), (IOL placements). An integrated service for screening diabetes patientsEyePrevent. and others for diseases that retinal could lead to blindness. MANAGEMENT CEO Jeroen Cammeraat, COO Thomas van Elzakker, CFO Egbert Houwer, YEAR FOUNDED 2007 EMAIL [email protected] [email protected] TELEPHONE +31 70 399 3112 ADDRESS Mauritskade 35 2514 HD Den Haag Netherlands CONTACTS Jeroen Cammeraat Chief Executive Officer Hubert Tanja PA WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Inc. Therapeutics, Juventas www.juventasinc.com FINANCIAL SUMMARY Partners, Venture Medical Triathlon include: Investors The Company $30.2 million in venture funding. has raised Venture Reservoir Ventures, Takeda Ventures, New Science Early Stage Partners, Ventures, Fletcher Spaght The Company has JumpStart. Angel Fund and North Coast Co., Venture Blue Chip Investors, Venture Partners, Global Cardiovascular Fund, million in grantbrought in an additional $2.5 through the Ohio BioValidation funding and the QTDP Grant. the Center for Stem Cell and Regenerative Medicine, Innovation Center, PROFILE COMPANY Therapeutics is a clinical-stage regenerative medicine company therapies developing novel for Juventas is a non-viral plasmid that encodes for stromal cell- JVS-100, lead product, The company’s ischemic disease. to significantly SDF-1 has been shown increase end-organ function following tissue (SDF-1). derived factor-1 and promoting new injury damaged recruiting endogenous stem cells to the region, by promoting cell survival, The SDF-1 repair pathway is well conserved end-organ systems including the throughout blood vessel growth. and nervous system providing the opportunity to impact a broad range vasculature, dermis, kidney, brain, heart, clinical indications address large markets with high unmet medical need and significant Target of diseases. market potential. In 2012 the company initiated trials for two Phase II clinical use of JVS-100 to treat patients with critical limb are being conducted at the trials 16 sites Together, ischemia (CLI) and to treat patients failure (HF). with heart Phase I study results in patients with heart failure demonstrated that JVS-100 is well in the US and abroad. with patients showing significant improvements in key six minute walk functional parameters including tolerated, to complete the two Juventas has raised sufficient funds NYHA class. and Quality of Life (QOL), distance (6MWd), Phase II clinical trials. MANAGEMENT President and CEO Ph.D., Aras, Rahul Chief Medical Officer Ph.D., M.D., Marc Penn, Product Development Vice President, Ph.D., Joseph Pastore, Business Development Vice President, M.D., Paul Resnick,

YEAR FOUNDED 2007 EMAIL [email protected] FAX +216 359 0099 TELEPHONE +216 273 4000 ADDRESS Avenue 3615 Superior Suite 4403C OH 44114 Cleveland, CONTACT Ph.D. Aras, Rahul President and CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Technologies KLOX www.kloxtechnologies.com FINANCIAL SUMMARY Invested $25M to date. PROFILE COMPANY is a privately-owned company currently developing innovative and highly Technologies™ KLOX Based in Canada, Tissue Repair and Dentistry. effective therapeutic and cosmetic solutions for Dermatology, use in the fields of It has therapeutic has succeeded in evolving the use of light in treatments to a new level. Technologies KLOX which consists of a primary multi- developed an innovative technology platform; System, the KLOX Biophotonic The element-rich photo converter gel is applied to the area LED light device and a topical photo converter gel. The interactions that aid in the creation take place of an which is then illuminated by the lamp. being treated, environment favoring repair. and other The innovative Biophotonic System is being evaluated in clinical studies for the treatment of acne, and non- non-thermal, It has shown itself to be non-abrasive, medical applications such as wound healing. with an encouraging safety profile to date. invasive, is dedicated to growing the sale of the cosmetic commercial activities across varied fields; Technologies™ KLOX Pharmaceuticals allows the company to streamline efforts and focus energiesValeant on dental products to wound healing and dental. becoming a leader in medical applications dermatology, in PIPELINE Europe and Canada and is ready for worldwide or Skin Rejuvenation: cleared for commercialisation in US, regional partnering controlled split face trial in Europe with results expected in Q1 2013; submission Acne: completed randomized, for regulatory approval in Europe for moderate 2013. to severe acne expected in Q2 Ready for worldwide or regional partnering and Canadian pressure ulcer Stage II and III pilot study in 2013. Initiating Healing: and completing U.S. Wound Initiating European pressure ulcer Stage III registration trial in 2013 Management Dr Lise Hebert, President & CEO VP & Chief of Finance and Operations Mariano Rodriguez, Healing Wound Head, David Burroughes, Clinical Head, Vezina, Denis IP Director, Yamac, Tuba R&D Director, Eric Desrosiers, BD Director, Jody Engel, Regulatory Arana, Director, Flor del Pilar Operations Director, Isabelle Harvey, YEAR FOUNDED 2007 EMAIL [email protected] [email protected] FAX 450-680-4549 TELEPHONE 450-680-4571 Lise Pharand: ADDRESS Armand Frappier 275 Quebec Laval, H7V 4A7 CONTACTS Dr Lise Hebert President & CEO Lise Pharand Executive Secretary WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Therapeutics Lipopharma www.lipopharma.com FINANCIAL SUMMARY The company is Spain. in Palma de Mallorca, headquartered Lipopharma is a private company founded in 2006, financed privateby independent investors and founders. A) and research grants for and is now looking 7M+ in capital (seed + series Eur. Lipopharma has so far raised to complete PII trials of Minerval8 million Euros investment and to start regulatory in cancer in Europe and US AD and SCI products. preclinical development of IPO are currently partnership or being considered. capital, Venture PROFILE COMPANY Spain that is developing Lipopharma is a pioneering biopharmaceutical company de Mallorca, based in Palma a novel and unique Therapy (MLT), a new generation of medicines associated the Membrane Lipid with The lead approach developed by scientists targeting the membrane lipids of the cell. our team of world reputed regulates through activation the lipid structure and composition of cancer cell membranes of Minerval, product, which causes an important reduction of Cyclin resulting in 1) PKC mild activation, sphingomyelin synthase (SMS), leading D-associated cell proliferation and 2) a normalization of the Ras/MAPK and PI3/Akt signaling pathways, studies Minerval® In pre-clinical to cancer cell differentiation and selective death has by autophagy/apoptosis. MIN-001- outperforming the drugs of reference. demonstrated very high anticancer activity and lack of toxicity, the first clinical PI/IIa study with Minerval other advanced solid tumors has already been in Glioma and 1203, Agencies and first patients will be enrolled in Q1 2013. authorized by the UK and Spanish Regulatory Spinal Cord Injury (SCI) and disease (AD), Alzheimer’s based programs testing) are in (in preclinical Other MLT AD suggest that LP226A1 has a very significant Initial results in two different animal models of Inflammation. disease modifying capacity and neurogenesis activity. was established in Boston area as a US subsidiary in 2011. Lipopharma Inc. Lipopharma is currently seeking for opportunities with leading players new partnership in the pharmaceutical and commercializationmarket in order to complete the clinical development of Minerval in oncology and advance based pipeline further develop the promising MLT as well as to AD and SCI, our programs in MANAGEMENT CEO & Co-founder MBA., Tur, Vicenç CSO & Co-founder Ph.D., Pablo Escriba, Prof. Research Director Ph.D., Xavier Busquets, Prof. Development Director (consultant) Ph.D., MD, Grahaem Brown, Quality and regulatory affairs (consultant) QP., Ph.D, Moreno, A. Marco Development & Director of US operations. Ph.D, Neil Dey,

YEAR FOUNDED 2006 EMAIL [email protected] [email protected] [email protected] FAX +34 97 143 9886 TELEPHONE +34 97 143 9886 ADDRESS Km.7,4. Valldemossa, Ctra. 2º C-8 Edif.17. ParcBIT. 07121 – Palma de Mallorca. Spain CONTACTS Tur Vicenç CEO & Co-founder Pablo Escriba Prof. CSO & Co-founder WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Mabimmune Diagnostics AG Diagnostics Mabimmune www.mabimmune.com FINANCIAL SUMMARY The Mabimmune technology was built upon a publically-fundedyear $1.2 million academic research effort 6 at to investors in Q1-2013 A financing has been opened for raising upper Further Series the University of Zurich. flagship infarction single digit financing for completing pre-IND studies and phase I trials for Mabimmune’s prevention medication and companion diagnostic. PROFILE COMPANY medications best infarction-prevention death reduce the risk of cardiovascular by The Problem: Today’s approximately 20% after one year. a human antibody medication 1. Product: InfarctPrevent is a clinical theranostic package consisting of: a companion diagnostic and 2. anticipated to reduce the risk of infarction by 34% based on pre-clinical trails, The blood test identifies the enzymatic blood test that identifies patients to the treatment. who will respond proprietary molecular targets found to significantlycontribute to both heart activity of F17 one of Mabimmune’s The medication (FlowMab) is a best-in-class human-derived antibody that neutralizes F17 and attack and stroke. FlowMab intravenously is designed to be administered at is anticipated to significantlyof infarction. lower the risk a personalized dose determined by diagnostic the companion blood test everymonths. 1-3 MANAGEMENT Mabimmune is directed by70 years of combined bioentrapreneurial a team with over experience and a As an expert in proven track record of extraordinary value-generation for early startups. biopharmaceutical target portfolio PhD (CEO) has discovered Mabimmune’s Chad Brokopp, Dr. cardiovascular molecular medicine, PhD (chairman) is a Hoerstrup MD, Simon P. Prof. and contributes 7 years of entrepreneurial experience. clinical and marketing a serial bioentrepreneur who provides seasoned expert in cardiovascular medicine and M. Roger Prof. expertise in clinical regulatoryexpertise in cardiovascular products and a long-standing affairs. corporations MD (board member) is a seasoned bioentrepreneur of several successful and has acquired, Nitsch, Prof. value of over $1bn. and executed successful human antibody partnering deals in combined negotiated, proven track record of conducting human antibody-based clinical has a MD (board member), Christoph Hock, who has designed and PhD (board member) is a seasoned biopharmaceutical executive Jan Grimm, Dr. trials. executed successful business activities for antibodies and has brought numerous products into human-derived largest pharmaceutical companies. lucrative co-development and partnering deals with the world’s YEAR FOUNDED 2011 EMAIL [email protected] FAX +41 44 755 46 47 TELEPHONE +41 (0)78 901 22 93 ADDRESS 13 Wagistrasse 8952 Schlieren Switzerland CONTACT Dr Chad Brokopp Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u MedGenesis Therapeutix Inc Therapeutix MedGenesis www.medgenesis.com FINANCIAL SUMMARY MedGenesis is privately held. PROFILE COMPANY Therapeutix (MedGenesis) is a privately-held company biopharmaceutical committed to developing MedGenesis and commercializing innovative therapeutics treatments to provide life-enhancing to patients with serious a minimally Delivery Enhanced MedGenesis is a worldwide leader in Convection (CED), neurologic diseases. disease, local treatmentCNS conditions such as Parkinson’s of invasive technique that provides for targeted, MedGenesis lead product GDNF for Brain Cancer and other severely debilitating diseases of the CNS. Epilepsy, disease is currently in Clinical Phase II. the definitive treatment of Parkinson’s MANAGEMENT Therapeutix Inc. Founder of MedGenesis Chairman & Chief Executive Officer, R.Psych., Ph.D., Erich Mohr, Chief Scientific Officer Ph.D., Christian Fibiger, H. President and Chief Financial Officer FICR, PMP, M.Sc., Johnson, A. Greg Chief Medical Officer M.D., MatthiasMatthias Luz,

YEAR FOUNDED 2006 EMAIL [email protected] ADDRESS Therapeutix Inc. MedGenesis FAX +1 (250) 386-3777 CONTACTS R.Psych Ph.D., Erich Mohr, Officer Chairman & Chief Executive TELEPHONE +1 (250) 386-3000 730-730 View Street 730-730 3Y7 V8W BC, Victoria, Canada WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u NeuroPhage Pharmaceuticals NeuroPhage www.neurophage.com FINANCIAL SUMMARY $7.0M A: Series $12.5M Series B: $9.0M Series B-1: PROFILE COMPANY The company has a NeuroPhage a breakthrough platform is developing for treating protein aggregation diseases. amyloid alpha synuclein, broad pipeline of drug candidates that uniquely target multiple misfolded amyloids (tau, other ALS and multiple Parkinson’s, Alzheimer’s, PrP) in several neurodegenerative diseases such as beta, orphan and ultra-orphan neurology indications such as Creuzfeldt Jacobs disease and tauopathies. has also shown recently study sponsored strong activity in an alpha synuclein The lead drug candidate NPT002, Based on the discovery Fox Foundation and is poised to enter Phase 1 clinical trials in 2014. by the Michael J. NeuroPhage is developing second generation displaying Ig fusions the of the mechanism of action of NPT002, Amyloid efficacy with Interaction Motif) and has already shown in-vitro and in-vivo active motif GAIM (General these compounds. NeuroPhage Développement and in 2007 with lead investors Mérieux raised $28.6M since its inception Shire LLC. MANAGEMENT President & CEO Jonathan Solomon, EVP & CFO Hampus Hillerstrom, CSO Ph.D., Richard Fisher, Clinical Development Lead M.D., Michael Grundman, SVP Preclinical R&D Ph.D., Kim Gannon, VP Regulatory Roxanne Bales, VP Manufacturing Ph.D., Jason Right, Director of Research Ram Krishnan Ph.D., Director of Research Tsubery Ph.D., Haim YEAR FOUNDED 2007 EMAIL [email protected] FAX +617-714 5469 TELEPHONE +617-412 5171 ADDRESS Third Street 222 Suite 3120 MA 02142 Cambridge, USA CONTACTS Hampus Hillerstrom (speaker VP & Executive Chief Financial Officer Jonathan Solomon President & Chief Executive Officer WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Numab AB Numab www.numab.com FINANCIAL SUMMARY moneyUp to CHF 5 million seed provided through industry collaboration. PROFILE COMPANY Numab company is a Swiss biotech that discovers and develops innovative antibody-based therapeutics. Numab proprietary is pursuing two programs antibody to develop first-in-class therapeutics for autoimmune under which Numab Numab has an ongoing multi-target collaboration with Sucampo, diseases and pain. development leads. discovers novel antibody-based This is technology has been designed to gain mayimal flexibility in antibody-based drug design. Numab’s achieved by engineering highly drug-like antibody variable potent and domains that allow for modular assembly These may be mono- or of molecules having and pharmacokinetic properties. the desired pharmacodynamic depending on the targeted kDa) molecular weight, bispecific molecules of low (26-50 kDa) or high (150-200 product profile. Numab is led by a Management track record in the biotech industry with proven (4 out of 5 Management members have key been long lasting employees in positions at ESBATech). MANAGEMENT PhD, CSO & Co-CEO David Urech, CBO & Co-CEO PhD, Oliver Middendorp, Head of Pharmacology PhD, Gunde, Tea Head of Biochemistry PhD, Sebastian Meyer, Administration Head of Finance and Roland Helfenstein, YEAR FOUNDED 2011 EMAIL [email protected] FAX +41 44 533 0470 TELEPHONE +41 44 533 0471 ADDRESS AG Numab Einsiedlerstrasse 34 Wädenswil CH-8820 Switzerland CONTACT Oliver Middendorp CBO & Co-CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u OBS Medical OBS www.obsmedical.com FINANCIAL SUMMARY Only availablerequest. on PROFILE COMPANY device and software innovation is a medical company that provides intelligent solutions to OBS Medical, biotechnology and clinical research companies. pharmaceutical, primary care practices, hospitals, MANAGEMENT CEO Peter Leyland, CFO Crispin Quail, YEAR FOUNDED 2000 EMAIL [email protected] FAX 0800 130 3108 TELEPHONE 01235 432050 ADDRESS Brook House 174 Brook Drive Milton Park Abingdon Oxfordshire OX14 4SD CONTACT Weatherall Chris Head Global QA/RA Unit Director BioQT Bus. WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Opexa Therapeutics, Inc. Therapeutics, Opexa www.opexatherpautics.co.uk FINANCIAL SUMMARY Opexa had approximately 2012, reporting forAs of its most recent periodic 30, the quarter ended September recently Opexa announced a strategic with Merck Serono which generated partnership an $2.2 million in cash. companyThe recently priced a private offering and potential milestones of $225 million. upfront fee of $5 million which generated million in gross $3.25 proceeds. PROFILE COMPANY (NASDAQ:OPXA) is a publicly biotechnology traded company dedicatedthe to Inc. Therapeutics, Opexa The company’s development of patient-specific cellular therapies for the treatment of autoimmune diseases. medical needs of the has the potential to address the significant unmet TcelnaTM, leading product candidate, large multiple sclerosis (MS) patient population. MANAGEMENT President & CEO Warma, Neil K. Affairs SVP Clinical Development & Regulatory PhD, Thompson, Jaye SVP Operations & Quality Systems Rill, Donna R. VP Scientific Development & Manufacturing PhD, Don Healey, YEAR FOUNDED 2004 EMAIL [email protected] FAX +1 281-872-8585 TELEPHONE +1 281-775-0600 ADDRESS Forest Blvd Technology 2635 Woodlands The TX 77381 USA CONTACTS Warma Neil K President & CEO WELCOME SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS

t back :: next u Ltd Therapuetics Opsona www.opsona.com FINANCIAL SUMMARY Biotechnology Company 0-20 Employees Private Company Latest – B Round Round of Funding date to – $35M Total Funding PROFILE COMPANY focused on novel therapeutic approaches to Opsona is a leading immunology company, drug development including key targets of the innate immune system associated with a wide range of major human diseases, disease and Alzheimer’s diabetes, cancer, transplant rejection, autoimmune and inflammatory diseases, atherosclerosis. College in Dublin one of Trinity The company was founded in 2004 by world-renowned immunologists three at a fully lead product, Opsona’s leading academic institution with a core focus on immunology research. Ireland’s (TLR2) has demonstrated activity in Toll-like-receptor-2 human monoclonal IgG4 antibody (OPN-305) targeting a number of animal models & recently successfully was tested in a phase 1 clinical trial in healthy volunteers. clinical study to double blinded